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ABSTRACT 
This dissertation describes the central regulation of GH secretion 
and mechanism of action of a substituted benzolactam GH secretagogue, 
L-692,585 (585), in male Yorkshire pig. 
The first study describes the central regulation of GH secretion by 
the GH-secretagogue, 585 with intracerebroventricular (icv) stainless steel 
cannulas placed by stereotaxic coordinates. Dose-dependent effects of 
585 were determined by icv injections of saline vehicle, 3, 10, 30 |j.g/kg 
BW by a once daily increment. A switchback study of iv and icv 585 
treatment was also performed to determine central and peripheral 
regulation of GH secretion by the GH secretagogue. 
The second study investigated the possible involvement of 
neuropeptides in GH secretion by using Yorkshire barrows with icv and 
iv cannulas. We administered somatostatin, neuropeptide Y and galanin 
with or without the nonpeptidyl GH secretagogue, 585 in the pig. The 
results indicate the possible involvement of SRIH, GAL and NPY in the 
central regulation of GH secretagogue-stimulated GH response. 
The third study tells the dose dependent effect of central urocortin 
on GH release. Three doses of urocortin [0.01, 0.03, 0.01 mg/kg BW] and 
saline vehicle administered via icv cannula. The results indicate the 
possible involvement of urocortin in GH release. 
vi 
The fourth study details the effect of 585 on central nervous 
^stem-adrenal function in Yorkshire pigs by comparing the effects of 
hypophysectomy (HYPOX) and sham operation control (SOC). Pigs were 
fitted with an indwelling cannulas in the anterior vena cava to determine 
sequential plasma profiles of GH, adrenocoticotropin [ACTH], and Cortisol 
secretion after ACTH, corticotropin releasing hormone [CRH], two doses 
of 585 (0.01, 0.1 mg/kg BW), and saline vehicle administration in 
HYPOX or SOC pigs. The results indicate that 585 did not directly 
increase Cortisol secretion in h3rpophysectomized pigs. The results also 
show that only a modest increase in ACTH plasma concentration induced 
by 585 may not involve the pituitary gland. 
The results of this study investigating the central effect of 585 
support the idea that these novel growth hormone secretagogues may 
mimic an unidentified endogenous hormone that amplifies and is capable 
of regulating pulsatile GH secretion in concert with GHRH, somatostatin, 
and neuropeptides. 
1 
GENERAL INTRODUCTION 
Literature review 
Identification of GH-secretagogue 
Exploring a small molecule that would cause growth hormone (GH) 
release from the pituitary gland led to a development of GH-
secretagogues. In 1984, Bowers and colleagues described a synthetic 
hexapeptide named GH-releasing peptide (GHRP-6) with strong GH-
releasing activity both in uitro and in muo. GHRP-6 has been 
demonstrated in several animal species and in humans (Clark et al., 
1989; nson et al., 1989; Bowers et al., 1990; Malozowski et al., 1991). 
Recently, a new hexapeptide (hexarelin) has been described and its 
chemical structure (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is 
similar to that of GHRP-6 (Deghenghi et al., 1992; Bowers, 1996). 
Hexarelin is a potent stimulator of GH secretion in several species 
including rats, humans and sheep (Wehrenberg et al., 1992; Ghigo et al., 
1994; GuiUaume et al., 1994). The discovery of the novel nonpeptidyl 
class of benzolactam GH secretagogues has stimulated considerable 
scientific and clinical interest. Merck researchers in 1988 embarked on a 
research program to discover a nonpeptidyl mimic of GHRP-6 and 
nonpeptidyl mimics of peptide agonists were extremely rare at that time 
(Wyvratt, 1996). Extensive study of structure-activity relationships 
(Bowers et al., 1980; Momany et al., 1981; Momany et al., 1984) 
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developed tlie prototype nonpeptidyl GH secretogogue, L-692,492, which 
is shown to be a well-tolerated and specific nonpeptidyl GH secretagogue 
in humans when administered intravenously (Gertz et al., 1993; Aloi et 
al., 1994; Gertz et al., 1994). Low oral bio-availability in animal models 
and modest potency in humans of L-692,429 initiated a detailed 
investigation of the structure-activity relationships for this benzolactam. 
L-692,585, a novel nonpeptidyl GH secretagogue analogue of L-692,429, 
was found to be approximately 20-fold more potent than L-692,429 in rat 
pituitary cell assays (Schoen et al., 1994) and in beagles in uivo (Jacks et 
al., 1994). A more potent analogue of L-692,429, L-692,585, was shown 
to initiate and amplify pulsatile release in guinea pigs, suggesting that 
this class of secretagogues may indeed mimic an endogenous hormone 
responsible for pulsatile GH release (Fairhall et al., 1995). These 
compounds were shown to be mimics of the synthetic peptide GH 
secretagogue GHRP-6 rather than of GHRH. The design of an alternative 
structural class of GH secretagogue to provide improved oral 
bioavailability started using 'privileged structures", ligands that bind to 
G protein-coupled receptors (Evans et al., 1986, 1988). MK0677 evolved 
through structural modification by selection based on inherent activity, 
specificity and oral bioavailability (Patchett et al., 1995). The oral 
bioavailability of MK0677, L-692,429 and GHRP-6 were >60 %, » 2% and 
< 1% respectively (Smith et al., 1996). 
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Receptor for GH-secretagogue 
By using highly specific ps]-labeled MK0677 as ligand. Pong et al. 
(1996) recently developed a radioreceptor assay that correlates with 
biological activity of the peptide and nonpeptide secretagogues and 
identified the specific receptor for GH-secretagogue. In binding assays, a 
series of compounds was evaluated: GHRH, somatostatin, met-
enkephalin gonadotropin-releasing hormone, thjrrotropin-releasing 
hormone, galanin, gastrin-releasing peptide, PHM-27, melanocyte-
stimulating hormone, isoproterenol, pheno^qrbenzamine, dopamine, 
bromocriptine, methoxamine, benoxathian, propanolol and clonidene. 
None of these compounds competed with p5S]-MK0677 binding (Smith et 
al., 1996). L-692,585, L-692,429, GHRP-6, hexarelin and a peptide 
antagonist, L-756,887, inhibit p5S]-MK0677 binding (Pong et al., 1996). 
MK0677 did not bind to the GHRH receptor and apparently MK0677 
binds to a new receptor in the control of GH release (Smith et al., 1996). 
The fact that GTP-y-S and GMP-PNP inhibit binding and Mg^-^ is required 
for binding suggests that the receptor is G protein coupled (Pong et al., 
1996). Identification for new GH-secretagogue receptor suggests possible 
existence of unidentified natural hormone. 
Mechanisms of Action GH-Secretagogue in vitro 
A perifusion ^stem consisting of primary cultures of rat pituitary 
cells was used to investigate the receptor difierence of GHRP-6 and 
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GHRH on GH secretion (Blake et al., 1991). When GHRH was perifused 
intravenously until GH secretion fell to basal levels, GHRP-6 caused 
second increase in GH secretion. Similar observations were made when 
the order of exposure to GHRH and GHRP-6 was reversed. The decrease 
in GH secretion observed with prolonged infusion of either secretagogue 
was not explained by depletion of GH pools in somatotrophs, but was 
associated with desensitization of distinct receptors or their signal 
transduction pathways (Smith et al., 1996b). Using the same perifusion 
^stem, primary cultures of rat pituitary cells GHRP-6, L-692,429 and L-
692,585 were proven to act through same receptor, and moreover in 
combination with GHRH, GHRP-6, L-692,429, and L-692,585 potentiated 
the effects of GHRH on GH secretion (Bowers et al., 1990). The effects of 
GHRH and GHRP-6 on intracellular adenosine 3',5'-cyclic 
monophosphate (cAMP) levels in rat pituitary cells were compared and in 
contrast to GHRH GHRP-6 did not increase cAMP (Smith et al., 1993). 
When the secretagogues were used in combination, the GHRH-induced 
increase in cAMP was potentiated (Smith et al., 1993, Cheng et al., 
1989). Utilization of kinase C pathway by the GH-secretagogue was 
investigated by using phorbol mjnistate acetate (PMA) exposed rat 
pituitary ceUs (Smith et al., 1993). Under these conditions, the effects of 
GHRP-6 were attenuated but the cells remained fully responsive to 
GHRH (Smith et al., 1993, Cheng et al., 1991), indicating GHRP-6 
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activates a G protein-coupled receptor that activates protein kinase C 
through phospholipase (Cheng et al., 1991). Using the perforated patch 
clamp technique, effects of GHRP-6 and L-692,429 on electrical activity 
of somatotrophs were monitored and found excitation and depolairization 
of the plasma membrane (Leonard et al., 1991). Substitution of sodium 
chloride with choline chloride in the pituitary cell culture medium did 
not prevent secretagogue-induced GH release (Leonard et al., 1991). This 
indicates that sodium channels are not involved in GHRP-6-induced GH 
release. Voltage-gated K channels were inhibited by concentrations of L-
692,429; L-692,585 active in inducing GH secretion (Leonard et al., 
1991; Pong et al., 1992; McGurk et al., 1993; Pong et al., 1993) and GH 
release induced by GHRP-6 or L-692,429 was inhibited by blockers of L-
type calcium channels (Smith et al., 1993; Pong et al., 1992). These 
results suggested blocking of K channels by GH secretagogue caused L-
type Ca channel active to stimulate GH release. It was reported that in 
human pituitary tumor cells L-692,429 and GHRP-6 markedly increased 
the rate of phosphatidylinositol turnover (Adams et al., 1995). The 
involvement of diacylglycerol and inositol triphosphates (IP3) in the 
GHRP-6 signal transduction pathway was also reported recentiy (Mau et 
al., 1995). GHRH activates adenylate cyclase to cause increases in 
intracellular cAMP, whereas MK0677 results in release of Ca^-^ from 
intracellular stores (Smith et al., 1996). 
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Mechanisms of Action GH-Secretagogoue in vivo 
In electrophysiological studies, GHRP-6 and L-692,585 
administered intravenously to rats caused excitation of secretory 
neurons in the arcuate nucleus (Dickson et al., 1993, 1995). GHRP-6, L-
692,429 and L-692,585, but not GHRH, activated c-fos expression 
selectively in the arcuate nucleus (Dickson et al., 1995), and this 
activation was associated with neurosecretory neurons (Doutrelant-
Viltart et al., 1995). This result suggested that GHRP-6, L-692,429 and 
L-692,585 acted directly or indirectly on the arcuate nucleus perhaps by 
targeting GHRH containing neurons (Smith et al., 1996). 
An experiment was designed to determine whether transection of 
the h5T)ophyseal stalk (HST), resulting in removal of hypothalamic inputs 
to the pituitary gland, would reduce sensitivity to L-692,585 to more 
closely mimic that observed in culture pituitary ceUs (Hickey et al., 
1996). Yorkshire castrate males were fitted with a catheter surgically 
implanted in the external jugular vein 3 days before HST or sham 
operation (SOC). L-692,585, GHRH, or both in combination were 
administered to animals and blood was collected sequentially for 
radioimmunoassay (RIA) of GH, Cortisol and luteinizing hormone (LH). 
There were no significant differences between HST and SOC groups in 
pretreatment GH levels before surgery. L-692,585 caused an acute 
increase in GH levels of similar magnitude in both groups with peak GH 
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at 10 minutes and returned to baseline by 60 minutes. GHRH alone 
increased peak GH concentration; however, L-692,585 plus GHRH 
caused an immediate sjmergistic increase in GH within 10 minutes. After 
HST and SOC, pretreatment GH levels were similar. The magnitude of 
GH secretion was markedly diminished in HST animals treated with L-
692,585, but, when GHRH was replaced exogenously, L-692,585 
provided GH release of magnitude indistinguishable from controls 
(Hickey et al., 1996), suggesting that GHRH is released by the 
hypothalamus in response to L-692,585. GHRH did not increase Cortisol 
levels when given alone or have an additive effect when administered in 
combination with L-692,585. Cortisol response to CRH challenge 
revealed that peak Cortisol before surgery was similar in magnitude in 
HST and SOC groups. The similarily of GH response to combined 
administration of L-692,585 plus GHRH in the HST and SOC groups 
confirms the ability of the HST pituitary to s3mthesize GH and respond 
maximally to appropriate stimuli. In addition, it demonstrates that the 
pituitary receptors that bind L-692,585 are expressed and that the 
synergism induced by coadministration of L-692,585 and GHRH in uivo 
occurs at the level of the pituitary. When the same HST pigs were treated 
with gonadotrophin releasing hormone and corticotrophin releasing 
hormone, a normal LH and adrenocorticotropic hormone (ACTH) 
response was measured, demonstrating that surgical intervention had 
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not compromised the functional integrity of the pituitary gland (Hickey et 
al., 1996; Chang et al., 1995). 
Modulation of pulsatile GH release by GH-secretagogue 
GH is normally released episodically, and the amplitude and 
number of oscillations are reduced during aging (Ho et al., 1987). 
Pharmacological intervention to treat GH deficiencies generally overrides 
the oscillators of GH axis. Because the oscillating nature of GH release is 
inherent to biological systems, this tightly controlled process presumably 
provides an optimal mechanism for hormone receptor-mediated 
activation/inactivation/reactivation of signal transduction cascades 
(Smith et al., 1996). 
The orally active GH secretagogue, MK0677, is indistinguishable 
from that activated by the synthetic peptide GHRP-6 (His-D-Trp-Ala-Trp-
D-Phe-Lys-NHa) first described by Bowers et al. (1977) and other GH 
secretagogues. MK0677 receptor is present in very low concentrations in 
the plasma membrane fraction of pituitary and hypothalamic tissue, and 
receptor activation synchronizes the pathways leading to GH release 
(Howard et al,, 1996). Chronic oral treatment of dogs once daily with 
MK0677 initiates an amplified pulsatile pattern of GH release that 
approximates a physiological profile (Smith et al., 1996). MK0677 
produced an episodic GH profile typical of normal physiology, and it 
leads to a conclusion that it may mimic a naturally occurring hormone 
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t±iat regulates pulsatile GH release (Smith et al., 1996). Understanding 
the GH- secretagogue mechanisms involved in the GH paradigm will be 
the first step to revealing the control of pulsatility of this hormone in the 
endocrine ^stem. 
Dissertation organization 
This dissertation consists of four papers, of which the first one has 
been submitted for publication in Endocrinology (1998). The second and 
fourth papers have been prepared for submission to Endocrinology and 
Progress in Neurobiology for publication, respectively. 
Abstracts of these two papers are being presented at the annual 
meeting of the Endocrine Society, New Orleans, June, 1998 and the 
annual meeting of the American Society of Animal Science/American 
Daily Science Association, Denver, July, 1998. The third and fourth 
papers on urocortin, control of GH release in the pig and L-692,585 on 
Cortisol release in hypophysectomized pigs will be presented initially as 
abstracts for the annual meeting of the Society for Neuroscience, Los 
Angeles, November, 1998. 
The papers are preceded by a general introduction and followed by 
a composite summary and general discussion. The literature cited in the 
General Introduction and General Discussion is listed after the General 
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Discussion section. All of the experimental and research work presented 
in this dissertation was carried out by myself in the laboratory and under 
the guidance of Dr. Lloyd L. Anderson. 
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CHAPTER 1. mXRACEREBROVENTRICULAR INJECTION 
OF GROWTH HORMONE SECRETAGOGUE, L-692,585, IN 
THE PIG: CENTRAL AND DOSE DEPENDENT EFFECTS ON 
GROWTH HORMONE SECRETION 
A paper submitted for publication in Endocrinology (1997) 
S. -J. Che, E. D. Mathias, L. L. Anderson, C. Chang, L. McNamara, E. 
Frazier, H. Chen, G. J. Hickey, and R. G. Smith 
ABSTRACT 
Central regulation of GH secretion by the GH-secretagogue, L-
692,585, was determined in Yorkshire barrows (40-45kg BW) with 
intracerebroventricular (icv) stainless steel cannulas placed by 
stereotaxic coordinates and indwelling external jugular vein (iv) cannulas 
fitted for injecting L-692,585 or saline and for serial blood sampling. 
Dose-dependent effects of L-692,585 were determined by icv injections of 
saline vehicle, 3, 10, 30 |ig/kg BW by a once daily increment. A 
switchback study of iv and icv L-692,585 treatment was also performed 
to determine central and peripheral regulation of GH secretion by the GH 
secretagogue at 30 fig/kg BW. L-692,585, dissolved in saline, was 
administered icv (150 fil) followed by 120 nl vehicle, and iv injection (300 
|il) was followed by 2 ml saline. Blood samples were collected and plasma 
GH levels (ng/ml) monitored over a 3-h period. When administered icv, L-
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692,585 increased GH concentration in a dose-dependent manner, with 
a return to baseline (< 10) by 60 min. Average peak GH response to iv and 
icv L-692,585 injection was 80 ± 10 (± SE) at 10 min and 53 ± 10 at 20 
min, respectively, in the switchback study. GH secretion was attenuated 
by increased numbers of icv injections (P < 0.05). Peak GH responses to 
the 1®^ through 4^ icv L-692,585 injections were 67 ± 18 at 20 min, 39 ± 
22 at 10 min, 20 ± 10 at 30 min, and 27 ± 9 at 20 min, respectively. GH 
secretion, however, was not affected by the increased numbers of iv 
injections of L-692,585. The results also showed that the L-692,585 icv 
injection significantly attenuated the response to the L-692,585 iv 
injection (P < 0.01); peak GH response to iv L-692,585 before and after 
icv L-692,585 injection was 97 ±14 and 62 ± 11, respectively. In contrast, 
L-692,585 iv injection did not significantly affect the GH response to icv 
L-692,585 injection (P > 0.05). Average peak GH to icv L-692,585 
injection before and after iv L-692,585 injection was 58 ± 17 and 49 ± 10, 
respectively. We conclude from intracerebroventricular administration 
that L-692,585 acts at the level of both pituitaiy and h3^othalamus. 
These findings demonstrate mechanisms differentially regulating GH 
secretion by the GH secretagogue, L-692,585, within the porcine 
hjrpothalamus and further suggest possible neuroendocrine roles of 
unidentified endogenous GHRP in the brain. 
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INTRODUCTION 
Growth hormone (GH] is released in a circadian, pulsatile fashion 
controlled by two hypothalamic hormones, GH releasing hormone (GRF) 
induces whereas somatostatin (SRIH) inhibits GH release. Development 
of the novel non-peptidyl growth hormone secretagogue, L-692,429, with 
potent GH releasing activity both in vivo and in vitro (1-4) provides a 
means to understand biological mechanisms of GH release. 
Blake and Smith (5) reported that L-692,429, a substituted 
benzolactam, acts in a manner identical to the peptidyl GH secretagogue 
GHRP-6 as described by Bowers et al. (6), but distinct from that of the 
endogenous GRF. L-692,585 is approximately 5- to 30-fold more potent 
based on in intra and in vivo studies, and with no detectable change in 
receptor specificity (7). Our preliminary experiment showed that L-
692,585 has a direct but limited action at the level of the pituitary gland, 
and that an intact hypophyseal stalk is required for a maximal GH and 
Cortisol response (8). A high affinity, stereospecific receptor for these 
nonpeptidyl GH secretagogues in rat and porcine anterior pituitary 
membranes and in rat hypothalamic membranes was determined by 
utilizing p2S]-MK0677, an orally active spiroindoline sulfonamide (9-11). 
Recent investigations strongly suggest that these secretagogues may 
mimic an unidentified endogenous hormone that amplifies and is capable 
of regulating pulsatile GH secretion in concert with GHRH and 
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somatostatin (12, 13). Intravenous administration of GHRP-6 or L-
692,585 to rats stimulated c-fos and electrical activity in the arcuate 
nucleus; this indicates a hypothalamic site of action {14, 15). 
We selected pigs as the species for this study because their 
responsiveness and specificity to this class of secretagogues closely 
resembles that of the human. Intracerebroventricular (icv) stainless steel 
cannulas were placed surgically to elucidate the nonpeptidyl GH 
secretogogues' (L-692,585) effect on central regulation of GH secretion in 
immature male castrates. A further understanding of central 
mechanisms by which L-692,585 controls GH release was determined by 
a) dose-dependent effects of icv administered L-692,585 and b) by a 
switchback design of icv and iv administered drug. 
MATERIALS AND METHODS 
Animals 
Fourteen Yorkshire castrated males, weighing 40-45 kg, were used 
in this study. Animals were housed in individual stainless steel 
metabolism crates for the duration of the study, and a com and soybean 
meal-based diet was available ad libitum. All care met or exceeded 
requirements in the Guide for Care and Use of Agricultural Animals in 
Teaching and Research (16). 
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Surgical procedures 
Pigs were anesthetized with an ear vein injection of sodium 
thiopental (0.14 mg/kg BW, Pentothal, Abbott Laboratories, North 
Chicago, IL) for endotracheal intubation and maintained on a closed-
circuit i^stem of halothane (2-5 %; Ayerst Laboratories, Rouses Point, 
NY) and ojQ^gen (300 cc/min) for the duration of surgeiy. An external 
jugular vein was surgically exposed, and a catheter (id. 1.27 nmi; od 2.29 
mm; Tygon microbore tubing. Fisher Scientific, Pittsburgh, PA) directed 
toward the cranial vena cava was inserted and sutured in place. The 
catheter was directed sc to the dorsal neck region and exteriorized 
between the scapulae for repeated blood sample collections. After 3 days, 
the animal's head was oriented in a large animal stereotaxic instrument 
(David Kopf Instruments, Tujunga, CA) so that the plane formed by the 
frontal and parietal bones was parallel to the instrument table top. An 
18-gauge stainless steel cannula was placed in the left lateral-cerebral 
ventricle according to predetermined coordinates (anterior-posterior, 
+ 14.0 mm; lateral, 6.0 mm to the bregma; horizontal, 18.0 mm to the 
dura mater). Two stainless steel screws and cranioplastic cement 
(Plastics One, Inc,. Roanoke, VA) secured the cannula. A backflow of 
cerebrospinal fluid indicated that the cannula was icv. To facilitate icv 
injections, the icv catheter was extended sc to the dorsal neck region and 
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exteriorized. Animal care and experimental protocols were approved by 
the Iowa State University Committee on Animal Care. 
Test compound and method of administration 
L-692,585 was dissolved in saline for iv and icv administration. 
Solutions were prepared at the beginning of each trial, so that solubilized 
L-692,585 was not stored longer than 1 day. L-692,585 or vehicle was 
administered icv in 150 nl solution and followed by 120 nl vehicle to fill 
cannula dead space. For iv injection 300 |al of L-692,585 or saline 
solution was followed by 2 ml vehicle (saline). To evaluate the integrity of 
the pituitary gland and as a positive control, the animals were challenged 
with corticortropin-releasing hormone (CRH; 150 (xg) and assayed for GH 
and Cortisol. pCRH (American Peptide Co., Inc., Sunnyvale, CA, USA) was 
dissolved in sterile saline (0.9% NaCl) and stored frozen (-80 C) in 150-|j1 
aliquots. Peptide hormone solutions were prepared at the beginning of 
each trial, so that solubilized CRH was not stored longer than 1 week. 
CRH or vehicle was administered icv in 150 td solution. This was followed 
by 120 nl saline to account for dead space in the catheter. 
Blood samples 
Blood (5 ml) was collected via an indwelling jugular cannula into 
heparinized tubes at each sampling. Samples were centrifuged, 1,500 x g 
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within 2 h, and plasma was harvested and stored at -20 C until hormone 
assay. 
Hormone assays 
A homologous porcine GH RIA was developed utilizing reagents 
supplied by Dr. A F Parlow, Pituitary Hormone and antisera Center, 
Harbor-UCLA Medical Center, Torrance, CA, USA (porcine GH [pGH] for 
iodination and standards, USDA-I-1; anti pGH, AFP 10318545). 
Sensitivity of the assay was 0.9 ng/ml. Intra- and inter-assay variations 
were 2.9 and 15.6 %, respectively. 
Plasma Cortisol concentrations were determined by a double-
antibody RIA similar to that described previously (17). Plasma Cortisol 
concentrations were quantified in duplicate 50-|al aliquots through the 
use of a solid-phase nonextraction technique. To validate the 
assay, known amounts of Cortisol were added to charcoal-stripped 
cortisol-free plasma as follows: 0.25, 0.5, 1.0, 2.5, and 5.0 ng/tube in 
quadruplicate. The plasma blank values were assayed and values were 
subtracted from those in tubes with known amounts of Cortisol. 
Sensitivity of the assay was 0.92 ng/ml, whereas intra- and inter-assay 
coefBcients of variation were 11.2 % and 2.5 %, respectively. 
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Experimental protocol 
Dose-response effect of L-692,585 icv injection on GH and Cortisol 
secretion 
Four pigs were used to determine the central dose dependent 
effects of L-692,585 and CRH on GH and Cortisol secretion (Fig. 1). 
Saline or L-692,585 at three dose levels (3, 10, 30 |Jig/kg BW) were 
administered by icv injections. Blood was collected at - 40, -20 
(pretreatment), 0, 10, 20, 30, 40, 60, 80, 100, 120, and 140 min (post 
treatment). 
Switchback study of L-692,585 iv and icv injection on GH secretion 
L-692,585 at 30 |ig/kg BW was administered to animals according 
to a switchback design outlined in Fig. 1. Blood was collected as 
described previously. 
Statistical analysis 
Mean pretreatment GH and Cortisol concentration as weU as post 
treatment peak GH and Cortisol concentration were obtained for each 
animal. Peak hormone level and peak occurring time were used to 
characterize hormone response profile of individual pigs. Data are 
expressed as the mean ± SE. All data were subjected to analysis of 
variance (ANOVA) to establish whether significant differences [P < 0.05) 
were present, in which case P values for pair-wise differences between 
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groups were calculated by Fisher's least square difference test or 
Satterthwaite approximate F-test of models appropriate for the 
experimental designs. 
RESULTS 
IntracerebTOventricular dose response effects ofL-692,585 and CRH on GH 
and Cortisol secretion 
After icv administration of L-692,585, plasma GH concentration 
increased in a dose-related manner, with a return to baseline by 60 mm 
(Fig. 2). GH peak response occurred at 10 min after 3 and 10 iig/kg L-
692,585 icv injection and at 20 min after 30 jig/kg L-692,585 icv 
injection. GH concentration after icv administration of CRH was similar 
to the saline control (P > 0.05). GH peak concentrations were 4 ± 0.9 
ng/ml (± SE), 3.5 ± 0.3 ng/ml, 24 ± 9 ng/ml, 35 ± 10 ng/ml, and 50 ± 9 
ng/ml for the saline control, CRH (150 ng) and L-692,585 (3, 10, and 30 
Hg/kg doses), respectively. 
There was no significant difference between dose-dependent 
groups in Cortisol levels (ng/ml) (Fig. 3). Administration of L-692,585 
resulted in Cortisol levels of similar magnitude in all groups compared 
with saline injected controls throughout 140 min. In contrast, Cortisol 
levels abruptly increased after CRH icv administration (P < 0.05) within 
10 min and remained high compared with saline and L-693,585 treated 
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groups. A modest increase to peak Cortisol levels occurred at 10 rain after 
L-693,585 administration with levels returning toward baseline by 40 
min. Cortisol peak concentrations were 41 ± 8, 75 ± 9, 52 ± 23, 52 ± 15, 
and 63 ± 18 ng/ml for the saline control, CRH (150 |ig), and L-692,585 
(3, 10, and 30 lag/kg doses), respectively. 
Interaction of L-692,585 intravenous and intracerebroventricular injection 
on GH secretion 
In the switchback study, pigs were injected iv or icv with saline or 
30 |ig/kg BW L-692,585 to determine peripheral and central action of the 
GH secretagogue. Average of peak GH response to the iv and icv L-
692,585 injection was 80 ± 10 ng/ml at 10 min and 53 ± 10 ng/ml at 20 
min, respectively (Fig. 4). GH secretion was attenuated with the increase 
in numbers of icv injection in the switchback study [P < 0.05). Peak GH 
responses from the first through fourth icv L-692,585 injection were 67 ± 
18 ng/ml at 20 min, 39 ± 22 ng/ml at 10 min, 20 ± 10 ng/ml at 30 min, 
and 27 ± 9 ng/ml at 20 min, respectively (Fig. 5). The data also showed 
that the L-692,585 icv injection significantly attenuated the response to 
the L-692,585 iv injection (P < 0.001). The average peak GH response to 
iv L-692,585 injection before and after icv L-692,585 injection was 97 ± 
14 and 62 ± 11 ng/ml, respectively (Fig. 6). In contrast, L-692,585 iv 
injection did not significantly affect the GH response to icv L-692,585 
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injection [P > 0.05). The average peak GH response to icv L-692,585 
injection before and after iv L-692,585 injection was 58 ± 17 and 49 ± 10 
ng/ml, respectively (Fig. 7). 
DISCUSSION 
The substituted benzolactam, L-692,492, in common with GHRP-6, 
has been shown to act directly on somatotrophs, causing GH release in 
several species including swine (18), rats (19), beagles (3), and man (2) 
and in combination with GRF results in synergist GH response (4). We 
describe for the first time in vivo potency of centrally administered L-
692,585, a nonpeptidyl GH secretagogue analogue of L-692,429, in 
eliciting GH release in swine. 
Transection of the h37pophyseal stalk (HST) in the pig resulted in a 
blunted but detectable GH response to L-692,585 iv injection. 
Remarkably, the 2-fold and 16-fold increase in GH secretion to L-
692,585 and GRF plus L-692,585, respectively in the HST Yorkshire 
barrows was similar in magnitude to that seen with these treatments in 
vitro with dispersed pituitary cells (8). The minimal GH response in face 
of the absence of hypothalamic SRIH tone in the HST animals also 
indicated that inhibition of SRIH tone, in itself, was not adequate to 
induce an intact response. A hypothalamic stimulus also seems to be 
required to elicit a peak GH response to the GH secretagogue. 
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lev administxation of L-692,585 over t±ie dose range of 3-30 jig/kg 
BW resulted in a dose-dependent abrupt increase in plasma GH levels. 
These dose-dependent responses to icv L-692,585 injection in the pig 
contrast with the previously reported lack of GH response following icv 
administration of the peptidyl mimic GHRP-6 in conscious rats (20, 21). 
Cortisol plasma levels fluctuated but without a significant change among 
dose-dependent groups of icv-injected L-692,585, whereas CRH icv 
administration clearly elevated circulating Cortisol concentration 
throughout the 140 min post treatment period. Cortisol increases have 
been observed with L-692,429 and GHRP-6 in dogs and humans (2, 3, 
22, 23). Similar modest elevations in Cortisol levels to these 
secretagogues suggest that this properly is inherent in its mechanism of 
action, but within the physiological range of daily circadian secretion 
(13). GHRP-6 has been suggested to stimulate CRH in the hypothalamus, 
which then synergizes with AVP at the corticotroph to release ACTH (24). 
Possible clinical significance of modulated Cortisol secretion in response 
to these secretagogues remains to be determined. 
The interactions of iv and icv L-692,585 administration and the 
effects of continuous injection in this switchback design revealed that the 
GH response to icv L-692,585 injection was delayed and lower than iv-
administered L-692,585. An attenuated GH response to icv L-692,585 
ordinal injection was clearly illustrated (Fig. 5), although the GH 
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response to the fourth icv L-692,585 injection was slightly higher than 
that to the third icv L-692,585 treatment, the difference was not 
significant. The GH responses to iv L-692,585 ordinal injection did not 
show any sign of attenuation. These findings may suggest different 
mechanisms of GH-secretagogue action regulating GH secretion by a 
direct pituitary stimulatory effect when L-692,585 is injected iv, and a 
slower less robust response to icv L-692,585 via GRH and SRIH neurons 
within the porcine hypothalamus. 
This switchback design also revealed that there was a significant 
difference in the GH response to iv L-692,585 injection before and after 
icv administered L-692,585. In contrast, L-692,585 iv injection did not 
influence the GH response to icv injection of the secretagogue. There 
might be a feedback action to GHRP that directly stimulated the brain. 
Chaung et al. identified specific binding sites in rat and porcine anterior 
pituitary membranes and in rat hypothalamic membranes with MK0677, 
another class of GH secretagogue (10). Pong et al. suggested that the 
secretagogue mimics an unidentified endogenous hormone that amplifies 
and is capable of regulating pulsatile GH secretion in concert with GRF 
and somatostatin (12). 
Neuropeptide Y (NPY) exerts a negative influence on GH secretion 
possibly through either stimulating SRIH neurons or by inhibiting GHRH 
neurons. NPY-containing neurons have been reported to be located near 
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GHRH neurons in the arcuate nucleus (ARC) and express GH receptor 
roRNA (25). NPY neurons in the ARC express GH receptor, and surest 
that NPY neurons play a physiological role in feedback regulation of GH 
secretion (26). Galanin (GAL) is present in hj^othalamic magnocellular 
neurons of rat supraoptic nucleus and periventricular nucleus (27). GAL 
administration, either centrally or peripherally, increases plasma GH 
levels in the rat, presumably through stimulating GHRH directly because 
there are no binding sites for GAL on somatotrophs (28, 29). 
These findings demonstrate that L-692,585, administered iv or icv, 
is a potent GH secretagogue and confirm the proposed central role of L-
692,585 in the pig. Further studies are needed to determine why icv L-
692,585 elicited a slower and less robust GH response than that 
following iv L-692,585, and why desensitization occurred following 
repeated icv L-692,585 but not repeated iv L-692,585. 
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Experiment Design 
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FJg. 1, Dose response (Group 1) and switchback (Group 2 and 3) experimental designs Indicating time of 
hormone or vehicle administration to each pig relative to day of surgery. Siil icv: Saline icv; 585 icv: 30 
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Fig. 2. L-692,585 and CRM icv dose response in maJe castrate swine. 'Hie GH responses to L-692,585 
administered icv at 0 (saline vehicle), 3, 10, 30 Mg/kg BW and CRH at L5 |ag/kg BW. ITie values for each 
dose level were means for each tiiiK? point. 
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CHAPTER 2. INTRACEREBROVENTRICULAR INJECTION 
OF GALANIN, NEUROPEPTIDE Y AND SOBIATOSTATIN, 
ALONE OR WITH GH SECRETAGOGX7E, L-692,585, IN PIGS 
A paper prepared for submission to Endocrinology 
S. -J. Cho, L. L. Anderson, C. H. Chang, L. A. McNamara, E. Frazier, 
H. Chen, G. J. Hickey 
ABSTRACT 
To investigate the possible involvement of neuropeptides in GH 
secretion, we administered somatostatin (SRIH), neuropeptide Y (NPY) 
and galanin (GAL) with or without the nonpeptidyl GH secret^ogue, L-
692,585 (585) in the pig. In Yorkshire barrows (n = 9, 40-45 kg BW), an 
intracerebroventricular (icv) stainless steel cannula was placed by 
stereotaxic coordinates, and an indwelling external jugular vein (iv) 
cannula was fitted for repeat blood sampling. SRIH (2 or 8 tig/kg BW), 
NPY (4 ng/kg BW) or GAL (4 ^g/kg BW) were administered icv (150 nl) 
alone or with L-692,585 (30 i^g/kg BW). Blood samples were collected 
and plasma GH levels were monitored over a 3-h period. Average peak 
GH response (ng/ml) following icv administration of 2 or 8 i^g/kg SRIH [3 
± 0.6, 2 ± 0.3 (± SE), respectiLvelyj was significantly decreased (P < 0.05) 
compared with saline alone (4 ±0.9). Peak GH response following 2 or 8 
K^g/kg SRIH + L-692,585 (31 ± 5, 31 ± 7, respectively) was significantly 
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lower (P < 0.05) than L-692,585 alone (50 ± 9). GH response (ng/ml) 
following icv administration of NPY (3 ± 1) was not different from saline 
injection {P> 0.05). NPY + L-692,585 increased GH (25 ± 3); however, the 
response was less than GAL + L-692,585 or L-692,585 alone (P < 0.05). 
Average peak GH response following icv administration of GAL (11 ±3) 
was significantly increased (P < 0.05) compared with saline control (4 ± 
0.9). The GH response (AUG, ng miti-^ml-^) was similar (P > 0.05) 
following icv administration of GAL + L-692,585 (876 ± 106) and L-
692,585 alone (1284 ± 321). These results indicate the possible 
involvement of SRIH, NPY and GAL in the central regulation of GH 
secretagogue-stimulated GH response. 
INTRODUCTION 
Growth hormone (GH) is released in a circadian, pulsatile fashion 
regulated by neurohormones released from secretoiy neurons 
terminating in the median eminence of the h3^othalamus [1]. Major 
hypothalamic hormones controlling the release of GH are GH releasing 
hormone (GHRH) and somatostatin (SRIH). SRIH neurons projecting to 
the median eminence (ME) can be found in the periventricular 
hypothalamic and medial-basal amygdaloid nuclei [1]. In the external 
layer of the ME, axonal terminals of GHRH and SRIH show the same 
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pattern of distribution and close proximily to one another [2]. 
Development of the novel non-peptidyl growth hormone secretagogue, L-
692,429, with potent GH releasing activity both in vivo and in vitro (3-6) 
provides a means to understand biological mechanisms of GH release. 
Other neuropeptides that regulate GHRH-stimulated GH release in 
vivo include neuropeptide-Y (NPY), galanin (GAL) and as yet unidentified 
endogenous GH-releasing peptide (GHRP) that participates in regulation 
of GH release [7]. Nonpeptide mimetics of GHRP-6 with improved 
pharmacokinetics and oral availability (L- 692,429, L-692,585, MK-0677) 
are potent stimulators of GH release and greatly enhance GHRH-
stimulated GH release in the pig [4,8,9]. Although an endogenous GHRP 
has yet to be identified, a heterotrimeric GTP-binding protein-coupled 
receptor in pituitary and in the arcuate (ARC) ventro-medial and 
infundibular hypothalamus of swine and human has been cloned. 
Molecular characterization of this GH-secretagogue-receptor defines a 
novel neuroendocrine pathway for the control of pulsatile GH release and 
supports the idea that GH-secretagogue mimic an undiscovered hormone 
[10]. 
NPY is a 36 amino acid peptide that is widely distributed 
throughout the brain including hjrpothalamic neurons [II]. NPY-
containing neurons reported to be located near GHRH neurons in the 
ARC and express GH receptor mRNA [12, 13], whereas h3^othalamic NPY 
A1 
neurons residing outside the ARC do not [14]. GAL is a 29 amino acid 
amidated peptide originally isolated from porcine intestinal tracts by 
Tatemoto et al. [15] and present in hypothalamic magnocellular neurons 
of rat supraoptic nucleus (SON) and periventricular nucleus (PVN) [16]. 
GAL enhances GHRH-stimulated GH secretion in vivo that Ukely is 
mediated via a stimulatory effect on GHRH neurons in the hypothalamic 
ARC because there are no binding sites for GAL directly on somatotropes 
[17. 18]. 
Intracerebroventricular (icv) stainless steel cannulas were placed 
surgically to elucidate the nonpeptidyl GH secretagogue's (L-692,585), 
and neuropeptides' (SRIH, NPY, GAL) effect on central regulation of GH 
secretion in immature male castrate pigs. A further understanding of 
central mechanisms by which L-692,585 controls GH release was 
determined by a) Effect of SRIF with and without L-692,585 icv injection 
on GH secretion, b) Central effect of NPY with and without L-692,585 icv 
injection on GH secretion and c) Central effect of GAL with and without 
L-692,585 icv injection on GH secretion. 
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MATERIALS AND MBTHODS 
Animals 
Nine Yorkshire castrated males, weighing 40-45 kg, were used in 
this study. Animals were housed in individual stainless steel metabolism 
crates for the duration of the study, and a com and soybean meal-based 
diet was available ad libitum. All care met or exceeded requirements in 
the Guide for Care and Use of Agricultural Animals in Teaching and 
Research (19). 
Surgical procedures 
Pigs were anesthetized with an ear vein injection of sodium 
thiopental (0.14 mg/kg BW, Pentothal, Abbott Laboratories, North 
Chicago, IL) for endotracheal intubation and maintained on a closed-
circuit system of halothane (2-5 %; Ayerst Laboratories, Rouses Point, 
NY) and oxygen (300 cc/min) for the duration of surgery. An external 
jugular vein was surgically exposed, and a catheter (id. 1.27 mm; od. 
2.29 mm; Tygon microbore tubing. Fisher Scientific, Pittsburgh, PA) 
directed toward the cranial vena cava was inserted and sutured in place. 
The catheter was directed sc to the dorsal neck region and exteriorized 
between the scapulae for repeated blood sample collections. After 3 days, 
the animal's head was oriented in a large animal stereotaxic instrument 
(David Kopf Instruments, Tujunga, CA) so that the plane formed by the 
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frontal and parietal bones was parallel to the instrument table top. An 
18-gauge stainless steel cannula was placed in the left lateral-cerebral 
ventricle according to predetermined coordinates (anterior-posterior, 
+ 14.0 mm; lateral, 6.0 mm to the bregma; horizontal, 18.0 mm to the 
dura mater). Two stamless steel screws and cranioplastic cement 
(Plastics One, Inc,. Roanoke, VA) secured the cannula. A backflow of 
cerebrospinal fluid indicated that the cannula was icv. To facilitate icv 
injections, the icv catheter was extended sc to the dorsal neck region and 
exteriorized. Animal care and experimental protocols were approved by 
the Iowa State University Committee on Animal Care. 
Test compound and method of administration 
SRIH 1-14 (Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-
Ser-Cys, American Peptide Co., Sunnyvale, CA), porcine GAL (Gly-Trp-
Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-
Arg-Ser-Phe-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-His-Asp-Lys-Tyr-Gly-
Leu-Ala-NHa, American Peptide Co., Sunnyvale, CA) and porcine NPY 
Ciyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Leu-
Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-
Arg-iyr-NHa, American Peptide Co., Sunnyvale, CA) were dissolved in 
sterile saline (0.9 % NaCl) and stored frozen (-80 °C). L-692,585 was 
dissolved in saline for icv administration. Peptide hormone and L-
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692,585 solutions were prepared at the beginning of each trial so that 
solubilized peptide hormone and L-692,585 was not stored longer than I 
day. Peptide hormone solution (SRIH, GAL, NPY) with or without L-
692,585 or vehicle was administered icv in 150 pd solution and followed 
by 120 jil vehicle to Sll cannula dead space. 
Blood samples 
Blood (5 ml) was collected via an indwelling jugular cannula into 
heparinized tubes at each sampling. Samples were centrifuged at 1,500 x 
g within 2 h, and plasma was harvested and stored at -20 C until 
hormone assay. 
Hormone assays 
A homologous porcine GH RIA was developed utilizing reagents 
supplied by Dr. A F Parlow, Pituitary Hormone and antisera Center, 
Harbor-UCLA Medical Center, Torrance, CA, USA (porcine GH [pGH] for 
iodination and standards, USDA-I-1; anti pGH, AFP 10318545). 
Sensitivity of the assay was 0.9 ng/ml. Intra- and inter-assay variations 
were 2.9 and 15.6 %, respectively. 
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Experimentai protocol 
Dose-response effect of SRJF with and u/rthout L-692,585 icv injection on 
GH secretion 
To determine the central dose dependent effects of SRIF with and 
without L-692,585 on GH secretion nine pigs were used {Fig. 1). Two 
dose of SRIF (2, 8 M-g/kg BW] with and without L-692,585 at one dose 
level (30 p-g/kg BW), L-692,585 alone or saline was administered by icv 
injections. Blood was collected at - 40, -20 (pretreatment), 0, 10, 20, 30, 
40, 60, 80, 100, 120, and 140 min (post treatment). 
Central effect of NPY and GAL with and without L-692,585 icv injection on 
GH secretion 
To determine the central effects of NFV and GAL with and without 
L-692,585 on GH secretion nine pigs were used (Fig. 2, 3). One dose of 
NPY or GAL (4 |ig/kg BW) with and without L-692,585 at one dose level 
(30 lig/kg BW) was administered by icv injections. Blood was collected at 
- 40, -20 (pretreatment), 0, 10, 20, 30, 40, 60, 80, 100, 120, and 140 min 
(post treatment). 
Statistical analysis 
Mean pretreatment GH concentration as well as post treatment 
peak GH concentration were obtained for each animal. Peak hormone 
level and peak occurring time were used to characterize hormone 
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response profile of individual pigs. Data are expressed as the mean ± SE. 
All data were subjected to analysis of variance (ANOVA) to establish 
whether significant differences (P < 0.05) were present, in which case P 
values for pair-wise differences between groups were calculated by-
Student's t test. 
RESULTS 
Dose-response effect of SRIH with and without L-692,585 icv injection on 
GH secretion 
Average peak GH responses following icv administration of 2 or 8 
Hg/kg SRIH were 3 ± 0.6 and 2 ± 0.3 ng/ml (± SE), respectively which 
were decreased significantly compared with saline alone (4 ± 0.9) at 10 
min (P < 0.05). GH levels after 2 or 8 pig/kg SRIH treatment continued to 
drop until 30 min. Peak GH response following 2 or 8 ug/kg SRIH plus L-
692,585 were 31 ± 5 and 31 ± 7 ng/ml at 20 min, respectively. GH 
response after SRIH + L-692,585 was significantly lower than 50 ± 9 
ng/ml of L-692,585 alone at 20 min (P < 0.05, Fig. 1). However, there 
were no differences between two different doses (2 or 8 ug/kg) of SRIH 
alone or together with L-692,585 in GH response. 
Central effect of NPY and GAL with and tuithout L-692,585 icv injection on 
GH secretion 
GH response following icv administration of NPY was 3 ± 1 ng/ml, 
which is not different from saline injection. NPY + L-692,585 increased 
GH release (25 ± 3) at 20 min significantly higher than saline control (Fig. 
2a). Average peak GH response following icv administration of GAL was 
11 ± 3 ng/ml at 20 min and significantly higher than saline control [P < 
0.05). Average peak GH response following icv administration of GAL + L-
692,585 was 42 ± 4 ng/ml at 10- min, which was significantly higher 
than GAL alone and saline control (P < 0.05, Fig. 2b). Average peak GH 
respone of L-692,585 alone (50 ± 9) was significantly higher than GAL + 
L-692,585 (36 ± 3) at 20 min, but the GH response (AUG, ng min-^ ml-i) 
was similar (P > 0.05) following icv administration of GAL + L-692,585 
(876 ± 106) and L-692,585 alone (1284 ± 321) (Fig. 2b). GAL alone 
increased GH release significantly (11 ± 3, P < 0.05), but NPY was neither 
increased or decreased GH response compared with saline control (Fig. 
3a). NPY + L-692,585 increased GH release considerably compared with 
saline control; however, the response was less than GAL + L-692,585 or 
L-692,585 alone (P < 0.05, Fig. 3b). 
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DISCUSSION 
Nonpeptide GH-secretagogues, such as L-692,585, have been 
reported to act directly on somatotrophs causing GH release and also 
stimulates GH secretion by acting in combination with GHRH and 
interrupting the inhibitory tone of SRIH on the somatotroph [6,81- Other 
neuropeptides that control GHRH-stimulated GH release in vivo include 
not only neuropeptide Y (NPY), galanin (GAL), but an as yet unidentified 
endogenous GH-releasing peptide (GHRP) [7]. We describe for the first 
time in vivo central effect of SRIH, NPY, and GAL on L-692,585, a 
nonpeptidyl GH secretagogue-induced GH secretion in swine. 
lev injection of L-692,585 caused abrupt increase in GH secretion 
in 20 min. Blocking of potassium channels by activation of specific 
receptor for GH secretagogue causes activation of L-type calcium 
channel, which synchronizes docking of GH-containing secretoiy 
granules to the plasma membrane [20, 21, 22]. SRIH decreased GH basal 
level possibly through the SRIH receptor on GHRH neurons in median 
eminance [23]. This result was contrary to the report of increased growth 
hormone levels in control rats by icv SRIH injections [24]. Central 
injection of SRIH together with L-692,585 decreased GH secretion by half 
compared with L-692,585 alone. Whether centrally injected SRIH 
decreased L-692,585 induced GH release by hyperpolarizing 
somatotrophs or by deactivating the GHRH neuron is unknown. Iv 
55 
injection of sandostatin, an analogue of SRIH, significantly decreased the 
fos protein expression induced by icv injecton of L-692,585 [251. The 
central action of GH secretagogues to induce fos protein expression in 
the arcuate nucleus appears to be subject to central inhibitory control by 
somatostatin. There was no dose dependent effect with 2 and 8 ng/kg of 
SRIH. 
Neuropeptide Y (NPY) is known to be involved in the central 
regulation of appetite, sexual behavior, and reproductive function. 
Whereas central administration of NPY strongly stimulates feeding in 
satiated animals, diet restriction or other unfavorable metabolic 
situations, such as diabetes, produce enhanced NPY gene expression and 
NPY release in the hypothalamus [26]. The NPY family of peptides, which 
includes NPY, peptide YY (PYY), and pancreatic polypeptide (PP), are 
found in the central and peripheral nervous system and display a wide 
array of biological activities. These actions are believed to be mediated 
through pharmacologically distinct G protein-coupled receptors, and, to 
date, three members of the NPY receptor family have been cloned. In. situ 
hybridization of mouse brain sections reveals expression of this receptor 
within discrete regions of the hypothalamus including the 
suprachiasmatic nucleus, anterior h5rpothalamus, bed nucleus stria 
terminalis, and the ventromedial nucleus with no localization apparent 
elsewhere in the brain. NPY may play a physiological role in the 
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regulation of GH secretion by acting via SRIH in tiie periventricular 
nucleus, as well as via the GHRH in the arcuate nucleus ARC of the 
medial basal hypothalamus (MBH). Neuron structures anterolateral to 
the MBH were required for NPY-induced inhibition of GH secretion, and 
SRIH may be likely the neurohumoral mediator of the effect of NPY on 
GH secretion [27]. NPY was not able to decrease the basal level of GH 
compared with the saline contol, but NPY significantiy decreased L-
692,585-induced GH release in this study. The interesting phenomenon 
was that GH response to NPY with L-692,585 injection was even less 
than that of SE?IH with L-692,585, which may indicate that NPY has 
more direct effect on L-692,585-induced GH response than does SRIH. 
Galanin (GAL) is a widely distributed 29 to 30 amino acid long 
neuropeptide with multiple biological effects. It inhibits glucose-induced 
insulin release, hippocampal acetylcholine release, hippocampal 
glutamate but not GABA release, and it lowers spinal excitability and 
firing of locus coeruleus neurons [28]. GAL alone in this study 
significantiy increased the GH secretion, which may due to stimulating 
GHRH neurons. lev injection of synthetic GAL elicited a dose-related 
increase in plasma GH in conscious rats [29]. Pretreatment with rabbit 
antiserum specific for rat GRF significantiy inhibited the plasma GH 
increase induced by icv injection of GAL and suggests that GAL-induced 
GH secretion in the rat is mediated at least in part by hypothalamic 
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GHRH [29]. GAL administration icv also resulted in a dose-dependent 
increase in plasma GH concentrations in sheep, and concurrent 
administration of somatostatin caused a delay in the GH response to 
galanin but did not inhibit the GH release [30]. 
Tanoh et al, [31] reported the effects of cholinergic modulation by 
hexamethonium (HEX), tetraethylammonium (TEA), pirenzepine (PIR), 
and neostigmine on GH secretion induced by icv injected GAL. 
Pretreatment with HEX, TEA, or PIR significantiy reduced the GAL-
induced GH secretion, and pretreatment with neostigmine or with a 
specific antisomatostatin. antiserum reversed the inhibition of GAL-
induced GH secretion by HEX [31]. Tanoh et al. [31] suggested that both 
nicotinic and muscarinic cholinergic mechanisms interact with the GAL-
induced GH secretion by modulating hypothalamic somatostatin release. 
GAL did not synergistically increased GH secretion together with L-
692,585, GAL may increase GH release via stimulating GHRH neurons 
and at the same time compete with L-692,585 to induce GH release. 
However, GAL, together with L-692,585, increased GH level significantiy 
higher than NPY with L-692,585. 
These results indicate the possible involvement of SRIH, GAL and 
NPY in the central regulation of GH secretagogue-stimulated GH 
response, and the control of GH secretion by GHRPs (presumed 
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endogenous GH secretagogue) is different from original concept of GHRH 
and SRIH control of GH secretion. 
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CHAPTER 3. INTRACEREBROVENTRICX7LAR INJECTION 
OF UROCORTIN IN THE PIG: DOSE DEPENDENT EFFECTS 
ON GROWTH HORMONE SECRETION 
A paper prepared as an abstract for the annual meeting of the Society for 
Neuroscience, Los Angeles, November, 1998 
S. -J. Cho, L. L. Anderson 
ABSTRACT 
Central regulation of GH secretion by the novel corticotropin-
releasing factor, urocortin, was determined in Yorkshire barrows (40-45 kg 
BW) with intracerebroventricular (icv) stainless steel cannulas placed by 
stereotaxic coordinates and indwelling external jugular vein (iv) cannulas 
fitted for injecting urocortin or saline and for serial blood sampling. 
Dose-dependent effects of urocortin were determined by icv injections of 
saline vehicle, 10, 30, 100 }ig/kg BW by a once daily increment. 
Urocortin was administered icv (ISO^d) followed by 120 |il vehicle. Blood 
samples were collected, and plasma GH levels (ng/ml) were monitored 
over a 3-h period. When administered icv, urocortin increased GH 
concentration in a reversed dose-dependent manner, with a return to 
baseline (<10) by 100 min. Average peak GH response to icv urocortin 
injection (10, 30, and 100 ng/kg BW] was 10 ± 5, 8 ± 3, and 3 ± 0.4 (± 
SE), respectively. 
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INTRODUCTION 
Urocortin is a recently identified neuropeptide of the corticotropin 
releasing factor (CRF) family in the mammalian brain [1]. Urocortin 
seems to be an endogenous ligand for corticotropin releasing factor 
receptors, in particular CRF type 2 receptor. The neuropeptide CRF is 
well known to act on the central nervous ^stem in ways that mimic 
stress and result in decreases in exploration, increases in sympathetic 
activity, decreases in parasympathetic outflow, and decreases in 
appetitive behavior. Urocortin binds with high affinity to the CRF2 
receptor and is more potent than CRF in suppressing appetite, but is less 
potent than CRF in producing anxiety-like effects and activation. Doses 
as low as 10 ng injected intracerebroventricularly were effective in 
decreasing food intake in food-deprived and free-feeding rats [2|. 
Possibility of releasing GH by urocortin has been little studied. In this 
study, we administered three doses of urocotin intracerebroventrically to 
Yorkshire pigs and examined GH profiles. 
BIATERIALS AND METHODS 
Animals 
Five Yorkshire castrated males, weighing 40-45 kg, were used in 
this study. Animals were housed in individual stainless steel metabolism 
crates for the duration of the study, and a com and soybean meal-based 
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diet was available ad libitum. All care met or exceeded requirements in 
the Guide for Care and Use of Agricultural Animals in Teaching and 
Research (3). Animal care and experimental protocols were approved by 
the Iowa State University Committee on Animal Care. 
Surgical procedures 
Pigs were anesthetized with an ear vein injection of sodium 
thiopental (0.14 mg/kg BW, Pentothal, Abbott Laboratories, North 
Chicago, IL) for endotracheal intubation and maintained on a closed-
circuit system of halothane (2-5 %; Ayerst Laboratories, Rouses Point, 
NY) and oxygen (300 ml/min) for the duration of surgeiy. An external 
jugular vein was surgically exposed, and a catheter (id. 1.27 mm; od 2.29 
mm; lygon microbore tubing. Fisher Scientific, Pittsburgh, PA) directed 
toward the cranial vena cava was inserted and sutured in place. The 
catheter was directed sc to the dorsal neck region and exteriorized 
between the scapulae for repeated blood sample collections. After 3 days, 
the animal's head was oriented in a large animal stereotaxic instrument 
(David Kopf Instruments, Tujunga, CA) so that the plane formed by the 
frontal and parietal bones was parallel to the instrument table top. An 
18-gauge stainless steel cannula was placed in the left lateral-cerebral 
ventricle according to predetermined coordinates (anterior-posterior, 14.0 
nmi; lateral, 6.0 nrni to the bregma; horizontal, 18.0 mm to the dura 
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mater). Two stainless steel screws and cranioplastic cement (Plastics 
One, Inc,. Roanoke, VA) secured the cannula. A backflow of 
cerebrospinal fluid indicated that the cannula was icv. To facilitate icv 
injections, the icv catheter was extended sc to the dorsal neck region and 
exteriorized. Animal care and experimental protocols were approved by 
the Iowa State University Committee on Animal Care. 
Test compound and xnetliod of administration 
Three doses of urocortin (0.01, 0.03, 0.1 mg/kg BW) were prepared 
for icv administration. Urocortin or vehicle was administered icv in 150 
nl solution and followed by 120 |il vehicle (saline) to fill cannula dead 
space. 
Blood samples 
Blood (5 ml) was collected via an indwelling jugular cannula into 
heparinized tubes at each sampling. Samples were centrifuged at 1,500 x 
g within 2 h, and plasma was harvested and stored at -20 C until 
hormone assay. Blood was collected at - 40, -20 (pretreatment), 0, 10, 
20, 30, 40, 60, 80, 100, 120, and 140 min (post treatment). 
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Hormone assays 
A homologous porcine GH RIA was developed utilizing reagents 
supplied by Dr. A F Parlow, Pituitary Hormone and Antisera Center, 
Harbor-UCLA Medical Center, Torrance, CA, USA {porcine GH [pGH] for 
iodination and standards, USDA-I-1; anti pGH, AFP10318545). 
Sensitivity of the assay was 0.9 ng/ml. Intra- and inter-assay variations 
were 2.9 and 15.6 %, respectively. 
Statistical analysis 
Mean pretreatment GH concentration as well as post treatment 
peak GH concentration were obtained for each animal. Peak hormone 
level and peak time were used to characterize hormone response profile 
of individual pigs. Data are expressed as the mean ± SE. All data were 
subjected to analysis of variance (ANOVA) to establish whether 
significant differences (P < 0.05) were present, in which case P values for 
pair-wise differences between groups were calculated by Student's t test. 
RESULTS 
Intracerebroventricular dose response effects ofurocortin on GH secretion. 
After icv administration of urocortin, plasma GH concentration 
increased in a reversed dose-related manner, with a return to baseline by 
60 min (Fig. 1). GH peak response occurred at 30 min after 10 and 30 
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fig/kg urocortin icv injection and at 80 min after 100 ng/kg urocortin icv 
injection. GH peak concentrations were 4± 1 (± SE), 10 ± 5 ng/ml, 8 ± 3 
ng/ml, and 3 ± 0.4 ng/ml, for the saline control, and urocortin (10, 30 
and 100 |ig/kg doses), respectively. 
DISCUSSION 
Corticotropin-releasing factor, a neuropeptide isolated from the 
mammalian brain [3], has been implicated in the mediation of the 
integrated physiological response to stress [4, 5|. Until recently, only one 
endogenous CRF had been isolated from the mammalian brain, 
suggesting that only CRF itself was directly involved in stress-induced 
behavioral changes, including anorexia [2J. However, another 
neuropeptide of the CRF family, urocortin, was identified [1] and 
reopened the question, suggesting a potential physiological role for 
endogenous urocortin in activating central CRF receptors. There are still 
many mysteries involving mechanisms of urocortin, and we studied 
several possible characteristics of urocortin, the including whether the 
centrally injected urocortin can induce the GH release. The lowest dose 
of urocortin induced the highest GH response, and the highest dose of 
urocortin failed to elicit GH response. This result may indicate the 
possiblity of urocortin involving GH regulation by stimulating a feedback 
mechanism. 
REFERENCES 
1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, 
Sutton S, Chan R, Tumbull AV, Lovejoy D, Rivier C, et al. 1995 
Urocortin, a mammalian neuropeptide related to fish urotensin I 
and to corticotropin-releasing factor. Nature 16: 287-292 
2. Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W, Koob 
GF 1996 Appetite-suppressing effects of urocortin, a CRF-related 
neuropeptide. Science 273: 1561-1564 
3. Curtis SE 1988 Guide for the Care and Use of Agricultural Animals 
in Agricultural Research and Teaching. Consortium for Developing 
A Guide for the Care and Use of Agricultural Animals in 
Agricultural Research and Teaching, Champaign, pp 1-74 
4. Vale W, Speiss J, Rivier C, Rivier J 1981 Characterization of a 41-
residue ovine h3rpothalaniic peptide that stimulates secretion of 
corticotropin and beta-endorphin Science 213:1394-1397 
5. Plotslqr PM 1991 Hypothalamic secretion of somatostatin and 
growth hormone releasing factor into the hypophysial portal 
circulation is reduced in streptozotocin diabetic male rats. J. 
Neuroendocrinol 3:1 
81 
6. Dunn AJ, Benidge CW 1990 Physiological and behavioral 
responses to corticotropin releasing factor administration is CRF a 
mediator of anxiety or stress responses? Brain Res Brain Res Rev 
15: 71-100 
Fig. 1. Urocortin icv dose response in maJe castrate swine. Hie GH responses to L-692,585 
administered icv at 0 (saline vehicle), 3, 10, 30 f.ig/kg BW. The values for each dose level were means ± 
SE for each time point. 
O) 
(0 
E (/) 
Q. 
75 
<D 
sz 
9-
0 
o. 
I 
O 
16 n 
14 -
12 -
10 -
8 -
6 -
4 -
2 -
0 
-60 -40 
-o- Pretreatment 
—Urocortin 0.01 mg/kg 
Urocortin 0.03 mg/kg 
Urocortin 0.1 mg/kg 
-o- Saline 
T 
OO 
J I 
—I 1 1 1 
80 100 120 140 
84 
CHAPTER 4. THE EFFECT OF SUBSTITUTED 
BENZOLACTAM GH SECRETAGOGUE, L-692,585, ON 
ADRENAL CORTISOL SECRETION IN 
HYPOPHYSECTOMIZED PIGS 
A paper prepared for submission to Progress in Neurobiology 
S. -J. Cho, E. D. Mathias, L. L. Anderson, C. H. Chang, L. A. McNamara, 
E. Frazier, H. Chen, G. J. Hickey 
ABSTRACT 
The objective of this study was to determine if the transient Cortisol 
increase following growth hormone secretagogue (GHS) administration in 
pigs is due to a direct action of the GHS at the level of adrenal cortex. 
Yorkshire castrated males (40-45 kg BW) were either hypophysectomized 
(HYPOX, n=6) or sham operated (SOC, 7i=5). Pigs were fitted with an 
indwelling jugular catheter for blood collection to monitor plasma profiles 
(15 min intervals from -30 to 480 min) of Cortisol, adrenocorticotrophin 
(ACTH), and GH secretion after i.v. administrations of saline vehicle, two 
doses of a nonpeptidyl GHS L-692,585 (585; 0.01, 0.1 mg/kg), and ACTH 
(0.15 mg). Compared to saline, administrations of 585 at both doses 
significantly (P<0.05) increased Cortisol (38±12 vs 72±10, 91±9 ng/ml) in 
the SOC group, but not (P>0.05) in the HYPOX group (11±3 vs 15±6, 13±5 
ng/ml). Administrations of 585 at both doses significantly (-P<0.05) 
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increased ACTH {19±4 vs 121±20, 160±38 pg/ml) in t±ie SOC, but not in 
the HYPOX group (19±2 vs 18±5, 22±7 pg/ml). As expected, 
administrations of 585 at both doses significantly (P<0.05) increased GH 
(2.3dh0.5 vs 74±5, 83±17 ng/ml) in the SOC, but not (P>0.05) in the 
HYPOX group (2.2±3.4 vs 2.1±0.5, 1.7±0.5 ng/ml). ACTH was 
administered to serve as a positive control for adrenal Cortisol secretion. 
Compared to their respective saline controls, administration of ACTH 
caused increases in Cortisol levels in the SOC (38±12 vs 55±18 ng/ml, 
P>0.05) and HYPOX (11±3 vs 43±17 ng/ml, P<0.05) groups, respectively. 
Results of this study indicate that 585 requires an intact pituitary to 
increase Cortisol secretion suggesting that GHS has no direct stimulatory 
effect on the adrenal Cortisol secretion in pigs. (National Pork Producers 
Council 96-3316) 
INTRODUCTION 
The discovery of the novel nonpeptidyl class of benzolactam GH 
secretagogues has stimulated considerable scientific and clinical interest 
and given new insight in central regulation of GH secretion. Ever since 
the first GH releasing hexapeptide, GHRP-6, was described as a potent 
GH-specific secretagogue [1], there has been considerable development in 
GH secretagogue itself and its physiological function. L-692,585 is one of 
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a novel nonpeptidyl GH secretagogues, an analogue of L-692,429, was 
found to be approximately 20-fold more potent than L-692,429 in rat 
pituitary cell assays [2] and in beagles in vivo [3]. MK0677 evolved 
through structural modification by selection based on inherent activity, 
specificity and oral bioavailability [4]. 
Although an endogenous GHRP has yet to be identified, a 
heterotrimeric GTP-binding protein-coupled receptor in pituitary and in 
the arcuate (ARC) ventro-medial and infundibular hypothalamus of swine 
and human has been cloned. Molecular characterization of this GH-
secretagogue-receptor defines a novel neuroendocrine pathway for the 
control of pulsatile GH release and supports the idea that GH-
secretagogue mimics an undiscovered hormone [51-
GH- secretagogues are specific for GH release with the exception of 
causing modest increases in adenocorticotropin (ACTH) and Cortisol 
which has been observed with L-692,429, GHRP-6, and MK0677 in dogs 
and humans [6-10]. The hypothalamic-pituitaiy axis controls adrenal 
Cortisol function through the release of ACTH. Plasma levels of Cortisol 
rise within minutes of the intravenous infusion of ACTH, increasing 2 to 
5 times by 30 minutes [II]. Whether GH-secretagogue directly stimulates 
ACTH or Cortisol secretion is unknown. 
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The techniques of hjrpophysectomy were used in this study to 
determine whether the h^-pothalamus-pituitaiy axis was involved in the 
mechanisms stimulating ACTH or Cortisol by L-692,585 and to critically 
test the direct effect of L-692,585 on the function of adrenal glands after 
hypophysectomy. A further understanding of central nervous system-
adrenal function in pig was determined by a) L-692,585 effect on GH 
secretion in h5rpophysectomized pigs b) L-692,585 effect on ACTH 
secretion in hypophysectomized pigs and c) L-692,585 effect on Cortisol 
secretion in hypophysectomized pigs. 
MATERIALS AND METHODS 
Animals 
Eleven Yorkshire castrated males, weighing 40-45 kg BW, were 
used in this study. Animals were housed in individual stainless steel 
metabolism crates for the duration of the study, and a com and soybean 
meal-based diet was available ad libitum. All care met or exceeded 
requirements in the Guide for Care and Use of Agricultural Animals in 
Teaching and Research (12). 
Surgical procedures 
Pigs were anesthetized with an ear vein injection of sodium 
thiopental (0.14 mg/kg BW, Pentothal, Abbott Laboratories, North 
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Chicago, IL) for endotracheal intubation and maintained on a closed-
drcuit system of halothane (2-5 %; Ayerst Laboratories, Rouses Point, 
NY) and oxygen (300 cc/min) for the duration of surgery. An external 
jugular vein was surgically exposed, and a catheter (id. 1.27 mm; od 2.29 
mm; lygon microbore tubing. Fisher Scientific, Pittsburgh, PA) directed 
toward the cranial vena cava was inserted and sutured in place. The 
catheter was directed sc to the dorsal neck region and exteriorized 
between the scapulae for repeated blood sample collections. 
Hypophysectomy was performed following a procedure described 
previously (13, 14). After 3 to 5 days HYPOX was performed by a 
transj5:ontal supraorbital approach. The stalk was severed by blunt 
dissection with spherical-tipped platinum probes and hypophysis cerebri 
was usually removed in one piece but occasionally taken out in several 
small pieces. The sella turcica was swabbed with Bouin's fixative to 
destroy any remnants of the pituitary tissue. In sham operated group 
(SOC), the animals were subjected to the same surgical procedures as 
the HYPOX animals including Lifting of the left cerebral hemisphere for 
an equivalent period of time as required for HYPOX, except that the 
hypophyseal stalk and hypophysis cerebri remained in situ. The Iowa 
State University Cormnittee on Animal Care approved animal care and 
experimental protocols. 
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Postoperative animal care 
Cortisone acetate (50 mg; Cortone, Merck Sharp, and Dohme, 
Rahway, NJ) was given im after surgery. Pigs were maintained in 
individual pens in a recovery room at 25 °C. The animals were monitored 
intensively throughout the 24-h day for evidence of elevated body 
temperature, respiration and heartbeat rates, and patterns of food 
consumption. The pigs were assisted to resume food and water 
consumption as soon as possible; recovery was normal, usually within 
36 h. 
Postmortem 
At the end of the experiment, the experimental and control pigs 
were killed by an overdose of sodium thiopental {0.14 mg/kg BW, 
Pentothal, Abbott Laboratories, North Chicago, IL) and decapitated. The 
completeness of the HYPOX was confirmed by examining for remnants of 
pituitary tissue in sella turcica. 
Test compound and metliod of administration 
Two doses of L-692,585 (0.01, 0.1 mg/kg BW) were dissolved in 
PBS for iv administration. Solutions were prepared at the beginning of 
each trial, so that solubilized L-692,585 was not stored longer than 1 
day. L-692,585 or vehicle was administered iv in 300 |il solution and 
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followed by 2 ml vehicle (PBS) to fill cannula dead space. The animals 
were also challenged with corticortropin-releasing hormone (CRH; 150 
ixg) and adrenocoticotropin (ACTH; 150 ^g) and assayed for GH, ACTH, 
and Cortisol. ACTH (American Peptide Co., Inc., Sunnyvale, CA, USA) and 
pCRH (American Peptide Co., Inc., Sunnyvale, CA, USA) was dissolved in 
sterile PBS (0.9% NaCl) and stored frozen (-80 C) in ISO-pil aHquots. 
Hormone solutions were prepared at the beginning of each trial, so that 
solubilized ACTH and CRH were not stored longer than 1 week. ACTH, 
CRH or vehicle was administered iv in 300 lal solution. This was followed 
by 2 ml PBS to account for dead space in the catheter. 
Blood samples 
Blood (5 ml) was collected via an indwelling jugular cannula into 
heparinized tubes at each sampling. Samples were centrifuged at 1,500 x 
g within 2 h, and plasma was harvested and stored at -20 C until 
hormone assay. Blood was collected at - 30, -15 (pretreatment), 0, 15, 
30, 45, 60, 75, 90, 105, 120, 180, 240, 360, and 480 min (post 
treatment). 
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Hormone assays 
RIA of plasma GH 
A homologous porcine GH RIA was developed utilizing res^ents 
supplied by Dr. A F Parlow, Pituitaiy Hormone and antisera Center, 
Harbor-UCLA Medical Center, Torrance, CA, USA (porcine GH [pGH] for 
iodination and standards, USDA-I-1; anti pGH, AFP 10318545). 
Sensitivity of the assay was 0.9 ng/ml. Intra- and inter-assay variations 
were 2.9 and 15.6 %, respectively. 
RIA of plasma ACTH 
Blood was collected in EDTA-coated tubes (Sarstedt, Newton, NC) 
and immediately placed on ice. Samples were centrifuged within 2 h, and 
plasma was harvested and stored at - 80 °C. Total plasma ACTH was 
measured by using a commercially available ACTH, double antibody 
RIA (Diagnostic Systems Laboratories, Webster, TX). The antibody had 
100% cross-reactivities with ACTH-(l-39) and ACTH-(l-24); cross-
reactivities with other peptides derived from POMC were negligible. 
Parallelism was determined by measuring 200, 100, and 50 pi pooled 
plasma from two pigs with high endogenous concentrations for 200, 100, 
and 50 (il plasma, after adjustment for dilution, were 363, 328, and 303 
pg/ml, respectively. Intra- and interassay variations were 6.2 % and 7.0 
%, respectively. The sensitivity of the assay was 6 pg/ml plasma. This 
RIA has been validated independentiy for use in the pig (15). 
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RIA of plasma Cortisol 
Plasma Cortisol concentrations were determined by a double-
antibody RIA similar to that described previously (16). Plasma Cortisol 
concentrations were quantified in duplicate 50-jil aliquots through the 
use of a solid-phase ^25i_ria. nonextraction technique. To validate the 
assay, known amounts of Cortisol were added to charcoal-stripped 
cortisol-firee plasma as follows: 0.25, 0.5, 1.0, 2.5, and 5.0 ng/tube in 
quadruplicate. The plasma blank values were assayed and values were 
subtracted from those in tubes with known amounts of Cortisol. 
Sensitivily of the assay was 0.92 ng/ml, whereas intra- and inter-assay 
coefEicients of variation were 11.2 % and 2.5 %, respectively. 
Statistical analysis 
Mean pretreatment GH, ACTH and Cortisol concentration as well as 
post treatment peak GH, ACTH and Cortisol concentrations were 
obtained for each animal. Peak hormone level and peak occurring time 
were used to characterize hormone response profile of individual pigs. 
Data are expressed as the mean ± SE. All data were subjected to analysis 
of variance (ANOVA) to establish whether significant differences [P < 
0.05) were present, in which case P values for pair-wise differences 
between groups were calculated by Student's t test. 
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RESULTS 
L-692,585 ejfect on GH secretion in hypophysectonrized pigs 
Average peak GH responses following two doses (0.01, 0.1 mg/kg 
BW) of iv administration of L-692,585 in SOC group were 74 ± 5 and 83 ± 
17 ng/ml at 15 min, respectively (Fig la). 0.01 and 0.1 mg/kg of L-
692,585 treatments in HYPOX group did not increase GH (2.1 ±0.5, 1.7 
± 0.5, respectively) compared with PBS control (2.2 ± 0.4) (Fig. lb). ACTH 
also did not increase GH release (1.3 ± 0.3) in HYPOX pigs (P > 0.05, Fig 
Ic). 
L-692,585 effect on ACTH secretion in hypophysectomizedpigs 
In SOC group, average peak ACTH releases following CRH and L-
692,585 (0.01, 0.1 mg/kg BW) administration were 83 ± 23, 121 ± 20, 
and 160 ± 38 pg/ml at 15 min, respectively which were significantly 
increased (P< 0.05) ACTH secretion compared with PBS control at 15min 
(19 ±4, Fig 2a). Average peak ACTH release after CRH and two doses of 
L-692,585 injection were 44 ± 26, 18 ± 5, and 22 ± 7, respectively in 
HYPOX group (Fig 2b). ACTH level after ACTH treatement in HYPOX 
group was 2,963 ± 564 pg/ml (Fig 2c). 
L-692,585 effect on Cortisol secretion in hypophysectomized pigs 
There was significant difference in Cortisol level (68 ±12, 75 ±4, 92 
± 9 ng/ml, respectively) after CRH, L-692,585 (0.01, 0.1 mg/kg BW), 
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from PBS injection (43 ± 12) in SOC group (P < 0.05) (Fig. 3a). There was 
no significant difference in Cortisol level (24 ±96, 15 ± 5,8, 13 ± 4.9, 11 ± 
3.2, respectively) after CRH, L-692,585 (0.01, 0.1 mg/kg BW), and PBS 
injection in HYPOX group (P > 0.05). L-692,585 (0.1 mg/kg BW) released 
Cortisol episodically from 75 min and onward (Fig. 3 b). ACTH 
administration in HYPOX group significantly increased Cortisol level (43 ± 
17 ng/ml, P < 0.05) compared with other treatment. 
DISCUSSION 
Nonpeptidyl GH secretagogue, L-692,585 and its family are a 
synthetic secretagogue that stimulates the release of GH by acting at 
both hypothalamic and pituitaiy sites. Family of GH releasing peptide 
(GHRPs) also consistently elicits small, but significant, increases in 
plasma concentrations of ACTH and adrenal steroids [17]. Hypothalamo-
pituitaiy-adrenal axis by GH-secretagogue has been studied [17, 18], but 
there has been no study examining CNS-adrenal aids by GH-
secretagogue. To investigate CNS-adrenal axis by GH secretagogues 
hypophysectomy tectmique has been utilized. Despite the obvious 
advantages of using the hypophysectomized (HYPOX) pig for investigating 
the endocrine control of mammary growth and lactation, there are few 
studies involving use of HYPOX pigs. The paucity of reports on the effects 
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of HYPOX in pig reflects difSculties encountered in the surgical removal 
of the pituitary gland from these animals. 
L-692,585 induced high GH response in sham operated (SOC) pigs 
which certify the integration of pituitary gland in SOC pigs. Corticotropin 
releasing hormone (CRH) did not increase or decrease GH response. In 
hypophysectomized pigs, GH-secretagogue, L-692,585 did not increase 
GH response which indicate pituitary is required for the normal GH 
secretagogue action. In activation experiment of the h3^othalamo-
pituitary-adrenal axis by GHRP-6 in conscious rats, they were injected 
intravenously with GHRP-6, CRH, AVP, or PBS, alone or in combination, 
and assayed for ACTH, corticosterone, and GH [18]. CRH and AVP 
increased plasma ACTH levels in all rats, whereas ACTH and 
corticosterone responses to GHRP-6 were variable and were dependent 
on the prevailing activity of the hypothalamo-pituitary-adrenal axis [18]. 
The GH responses to GHRP-6 were significantly greater in rats with low 
basal plasma ACTH and corticosterone levels than in rats with elevated 
ACTH and corticosterone levels [18]. 
GH responses to L-692,585 and ACTH were not different from GH 
response to PBS in h)T)ophysectomized pigs, but basal level of GH was 
persistant. GH mRNA sequences and GH inmiunoreactivity have been 
demonstrated in chicken brain and suggest that it is an extrapituitary 
site of GH synthesis [19]. Although less abundant than pituitary GH, the 
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expression of the GH gene in ciiicken brain likely has physiological 
relevance since significant concentrations of GH immunoreactivity were 
detected in h3^othalaniic and extrahypothalamic tissues. Numerous 
actions of exogenous pituitary GH on brain growth, neurochemistry, and 
behavior may reflect local neurocrine actions of neural GH, as GH-
binding activity and GH receptor mRNA are present in chicken 
hjrpothalamic and extrahjrpothalamic tissues [2, 19J. Additionally GH 
may penetrate the blood barrier and contribute to the GH pool in 
systemic circulation because low levels of GH immunoreactivity persist in 
hjrpophysectomized pigs. Local production of GH within the brain 
suggests that it has paracrine roles in modulating neural or 
neuroendocrine function. The GH secretagogue, L-592,585, releases GH 
from pituitary cell but whether a GH secretagogue such as L-692,585 
directly affects neural GH in vivo is questionable. 
Among the hypothalamic factors endowed with corticotropin 
secretagogue activity, CRH and vasopressin are considered the major 
physiological mediators of hypothalamic control of ACTH release [20]. 
ACTH basal level by PBS injection in HYPOX pigs was similar in SOC. 
ACTH level induced by L-692,585 and CRH in HYPOX was lower than in 
SOC, This result indicates that a modest increase of ACTH by GH-
secretagogue in SOC was from pituitary but regarding L-692,585 as a 
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corticotropin secretagogue is still questionable. High ACTH levels after 
ACTH iv injection in HYPOX pig indicate validity of ACTH assay. 
When effects of single and repeated intravenous administrations of 
L-692,585 on Cortisol level in beagles were evaluated, serum Cortisol 
levels were increased above PBS control levels in a dose-dependent 
manner; however, the increases were modest compared to the GH 
increases [21]. The Cortisol level in HYPOX pigs by L-692,585 or CRH 
administration was in normal physiological range of Cortisol secretion. 
ACTH administration in HYPOX pig caused a marked increased in 
Cortisol indicating validity of HYPOX surgeiy. 
The main finding was that the neither L-692,585 or CRH appear to 
have a direct effect on the adrenal gland to release Cortisol in HYPOX 
pigs. The results also suggest that pituitaiy is required for L-692,585 
induced GH release and the increase of ACTH by L-692,585 treatment in 
SOC pigs may involve CRH from brain origin. 
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GENERAL SUMMARY AND DISCUSSION 
General Summary 
In tlie first study, we investigated tlie central and dose dependent 
effects of L-692,585 on GH secretion by using intracerebroventricular 
injection. When administered icv, L-692,585 increased GH concentration 
in a dose-dependent manner, with a return to baseline. In the 
switchback study, pigs were injected iv or icv with PBS or L-692,585 to 
determine peripheral and central action of the GH secretagogue. GH 
secretion was attenuated by increased numbers of icv injections. GH 
secretion, however, was not affected by the increased numbers of iv 
injections of L-692,585. The results of switchback study also showed 
that the L-692,585 injection signiiicantly attenuated the response to the 
L-692,585 iv injection. In contrast, L-692,585 iv injection did not 
significantly affect the GH response to icv L-692,585 injection. We 
conclude from intracerebroventricular administration that L-692,585 
acts at the level of both pituitary and hypothalamus. These findings 
demonstrate mechanisms differentially regulating GH secretion by the 
GH secretagogue, L-692,585, within the porcine hypothalamus and 
further suggest possible neuroendocrine roles of unidentified endogenous 
GHRP in the brain. 
In the second study, the possible involvement of neuropeptides in 
L-692,585 induced GH secretion was investigated. Dose-response effect 
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of SRIF with or without L-692,585 icv injection and central effect of NPY 
and GAL with or without L-692,585 icv injection on GH were 
investigated. Average peak GH response following icv administration of 
SRIH was significantly decreased. Peak GH response following SRIH 
together with L-692,585 was reduced by half compared with L-692,585 
alone. NPY was not able to decrease the basal level of GH compared to 
the PBS control, but NPY significantly decreased L-692,585 induced GH 
release in this study. The interesting phenomenon was that GH response 
to NPY with L-692,585 injection was even less than that of SRIH with L-
692,585, which may indicate NPY has more direct effect on L-692,585 
induced GH response than SRIH. GAL alone in this study significantly 
increased the GH secretion which may be due to stimulating GHRH 
neurons. GAL did not synergistically increase GH secretion together with 
L-692,585. GAL may increase GH release via stimulating GHRH neurons 
and at the same time compete with L-692,585 to induce GH release. 
However, GAL together with L-692,585 increased GH level significantly 
higher than NPY with L-692,585. These results indicate the possible 
involvement of SRIH, GAL and NPY in the central regulation of GH 
secretagogue-stimulated GH response, and the control of GH secretion by 
GHRPs (presumed endogenous GH secretagogue) is different from 
original concept of GHRH and SRIH control of GH secretion. 
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In third study, central regulation of GH secretion by the novel 
corticotropin-releasing factor, urocortin, was determined in Yorkshire 
barrows {40-45kg BW) with icv cannulas. Dose-dependent effects of 
urocortin were determined by icv injections of saline vehicle, 10, 30, 100 
Hg/kg BW by a once daily increment. When administered icv, urocortin 
increased GH concentration in a reversed dose-dependent manner, with 
a return to baseline (<10) by 100 min. Lowest dose of urocortin induced 
highest GH response and highest dose of urocortin failed to stimulating 
GH response. This result may indicate the possiblity of urocortin 
involving GH regulation by stimulating feedback mechanism. 
The fourth study investigated the central nervous system [CNS]-
adrenal function of L-692,585 using hypophysectomized pigs. 
Nonpeptidyl GH secretagogue, L-692,585 and its family are a synthetic 
secretagogue that stimulates the release of GH by acting at both 
hypothalamic and pituitary sites. L-692,585 induced high GH response 
in sham operated (SOC) pigs which certify the integration of pituitary 
gland in SOC pigs. Corticotrophin releasing hormone (CRH) did not 
increase or decrease GH response. In hypophysectomized pigs, GH-
secretagogue, L-692,585 did not increase GH response which indicates 
that the pituitary is required for the normal GHRPs action. There was 
modest increase of ACTH in response to L-692,585 in sham operated 
pigs, which was significantly higher than in the PBS treated group. ACTH 
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level induced by L-692,585 and CRH in HYPOX was markedly lower than 
in SOC. This result indicates that modest increase of ACTH by GH-
secretagogue in SOC was from pituitary but regarding L-692,585 as a 
corticotropin secretagogue is still questionable. High ACTH level after 
ACTH iv injection in HYPOX pig indicates validity of ACTH assay. The 
Cortisol level in HYPOX pigs by L-692,585 or CRH administration was in 
normal physiological range of Cortisol secretion. ACTH administration in 
HYPOX pig caused a marked increased in Cortisol indicating validity of 
HYPOX surgeiy. The main finding was that the neither L-692,585 or CRH 
appear to have a direct effect on the adrenal gland to release Cortisol in 
HYPOX pigs. The results also suggest that pituitary is required for L-
692,585 induced GH release and the increase of ACTH by L-692,585 
treatment in SOC pigs may involve CRH from brain origin. 
General Discussion 
Pork is an important U.S. agricultural commodity and in 
expanding global markets. The role of growth hormone in nutrient 
partitioning is of paramount interest to improve protein production by 
livestock species. One primary objective of this thesis is to increase our 
understanding of central mechanisms focusing on metabolic regulators 
such as growth hormone secretagogue and their role in regulation of 
growth hormone secretion. 
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The hypothalamus in the lower part of the brain regulates both 
basal and episodic secretion of growth hormone, as well as the secretion 
of other anterior pituitary hormones such as prolactin, adrenocortropin, 
follicle stimulating hormone, luteinizing hormone, and thyroid 
stimulating hormone. For each of these anterior pituitary hormones, 
small brain peptides (from 189 to 5,108 molecular weight) stimulate or 
inhibit pituitary secretion of larger proteins (from 4541 to -32,000 
molecular weight). Growth hormone (GH) is released in a circadian, 
pulsatile fashion, that is controlled by two hypothalamic hormones, 
GHRH (GRF), which induces GH release, and somatostatin (SRIF) which 
is inhibitory. We have developed neurosurgical techniques of 
hypophysectomy and intracerebro-ventricular cannulation to determine 
central nervous system regulation of GH secretion in the young, growing 
pig. With these surgical interventions, selective brain peptide or pituitary 
hormone replacement is administered intravenously or 
intracerebroventricularly to determine acute regulation of GH release by 
radioimmunoassay of GH concentration in sequential blood samples. 
Discovery of small GH releasing peptides, such as GHRP-6 (His-D-
Trp-Ala-Trp-D-Phe-Lys-NHa), with potent GH releasing activity has led to 
a search for nonpeptidyl GH secretagogues with efficacy by oral 
administration. Our preliminary experiments by Hickey et al. (1996) to 
modulate GH release focused on mechanisms within the central nervous 
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^stem (CNS) by which a novel nonpeptidyl GH secretagogue, L-692,585, 
elicits acute GH release when administered alone and in combination 
with GHRH to amplify GH release in intact and hypophyseal stalk-
transected Yorkshire barrows. Recently, the receptor for GH-
secretagogue has been cloned in the pig, human, and rat and shown to 
be distinct from that of the GHRH receptor. 
The focus of this dissertation was determination of a nonpeptidyl 
GH secretagogue's effect on central regulation of GH secretion in pigs. 
These small peptide and peptidomimetic or non-peptide substituted 
benzolactams possessing GH secretagogue activity enhance GH 
amplitude without influencing pulse frequency likely by involvement of 
SHRH as the pulse regulator. Sites of action within the CNS for 
nonpeptidyl L-692,585 specifically track GHRH neurons in the arcuate 
nucleus within the hypothalamus. The GH secretagogues activate GHRH 
neurons within the arcuate nucleus to effect GH release by the pituitary 
and/or the GH secretagogues interfere with somatostatin receptors on 
arcuate neurons. Intracerebroventricular injection of GH elicits fos 
protein expression of somatostatin neurons in the periventricular 
nucleus (PVN), and neuropeptide-Y (NPY) neurons in the arcuate nucleus 
to inhibit further GH secretion. This occurs in spite of markedly 
increased circulating concentrations of GH as a result of GHRH injection. 
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Discovery of small peptidyl and nonpeptidyl GH-secretagogues with 
less than 500 molecular weight and recent elucidation of its receptor in 
the hypothalamus in the lower part of the brain and pituitary gland at 
the base of the brain allows search for sites of action to regulate growth 
hormone (GH) secretion. Rapid growth in the young pig requires an 
episodic pattern of GH secretion. Preliminary in vivo experiments of 
Hickey et al. showed that the nonpeptidyl GH-secretagogue, L-692,585 
had a direct stimulatory action at the level of the pituitary gland in the 
young growing pig, but an intact hjrpophyseal stalk connecting the 
pituitary gland to the hypothalamus was required for maximal GH 
response. The studies included in this thesis focused on determining the 
central nervous system (CNS) regulation of GH secretion by 
intracerebroventricular (icv) administration of the GH-secretagogue, L-
692,585 and effect of L-692,585 to CNS-adrenal axis. lev injection of GH 
secretagogue, L-692,585, caused an acute dose-dependent increase in 
GH response. Peak GH response to L-692,585 icv injection occurred 
within 10 to 20 minutes and averaged 23, 39 and 50 nanograms per 
milliliter of plasma for treatment doses of 3, 10 and 30 micrograms per 
kilogram of body weight. Peak episodic GH secretion in vehicle injected 
animals averages 4 to 6 nanograms per milliliter plasma. Specificity of 
the GH response by the GH secretagogue was indicated by a lack of GH 
release following icv injection of the brain peptide, corticotropin releasing 
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hormone (CRH); GH remained at basal plasma concentrations whereas 
an abrupt and sustained increase in plasma concentration of adrenal 
Cortisol occurred throughout 140 minutes. In contrast, Cortisol blood 
concentration remained within the normal physiological range after icv 
injection of the GH secretagogue. 
GH releasing hormone (GHRH) and somatostatin (somatotropin 
release-inhibiting hormone (SRIH or SRIF) are natural brain peptides 
that modulate the normal pattern of episodic secretion of GH throughout 
the 24 hour period of the day and night. Whether the L-692,585's 
mechanism of action within the brain involves SRIH and its receptor 
known to be present on arcuate neurons, the site of GHRH secreting 
neurons in the hypothalamus, was determined by icv injection of SRIH 
and the GH-secretagogue. lev injection of SRIH alone decreased basal 
plasma concentration of GH compared with PBS vehicle injection 
throughout 140 minutes. When L-692,585 plus SRIH were icv injected 
the peak GH response was decreased by half compared with L-692,585 
alone, suggesting a central role for SRIH in regulating the GH-
secretagogue induced GH response. Neuropeptide Y (NPY) and Galanin 
are neuropeptides, first isolated in the pig, that affect pituitary hormone 
secretion. Whether NPY and galanin increase or decrease GH-
secretagogue induced GH response was determined in this icv model. lev 
injection of galanin alone significantly increased peak GH release within 
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20 minutes, but galanin plus L-692,585 treatment did not significantly 
increase the GH response greater than L-692,585 alone. In contrast, GH 
remained at basal plasma concentration after icv injection of NPY alone, 
but NPY plus L-692,585 treatment significantly decreased peak GH 
response compared with L-692,585 alone. GH response to NPY with L-
692,585 injection was even less than that of SRIH with L-692,585, which 
may indicate NPY has more direct effect on L-692,585 induced GH 
response than SRIH. These results revealed central mechanisms by 
which a novel GH-secretagogue, L-692,585, can acutely release growth 
hormone in a dose-dependent manner, and a role for SRIH, galanin aad 
neuropeptide Y in modulating this GH response in the brain of the young 
growing pig. 
Urocortin is a recently identified neuropeptide of the corticotropin 
releasing factor (CRF) family in the mammalian brain [1]. Urocortin 
appears to be an endogenous ligand for corticotropin releasing factor 
receptors, in particular CRF receptor type 2. The neuropeptide CRF is 
well known to act on the central nervous system in ways that mimic 
stress and result in decreases in exploration, increases in sympathetic 
activity, decreases in parasympathetic outflow, and decreases in 
appetitive behavior. Since capacity of urocortin releasing GH was 
unknown, three doses of urocotin has been administered 
intracerebroventrically to Yorkshire pigs to examine GH profiles. Lowest 
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dose of urocortin induced highest GH response and highest dose of 
urocortin failed to stimulating GH response. This result may indicate the 
possiblity of urocortin involving GH regulation by stimulating feedback 
mechanism. 
Nonpeptidyl GH secretagogue, L-692,585 and its family are a 
synthetic secretagogue that stimulates the release of GH by acting at 
both hypothalamic and pituitary sites. Family of GH releasing peptide 
(GHRPs) also consistently elicits small, but significant, increases in 
plasma concentrations of ACTH and adrenal steroids. Hypothalamo-
pituitaiy-adrenal axis by GH-secretagogue has been studied, but there 
has been no study examining CNS-adrenal axis by GH-secretagogue. 
H5rpophysectomi2ed (HYPOX) pigs were used to investigate CNS-adrenal 
axis by GH secretagogues. L-692,585 induced high GH response in sham 
operated (SOC) pigs which certify the integration of pituitaiy gland in 
SOC pigs. Corticotropin releasing hormone (CRH) did not increase or 
decrease GH response. In hypophysectomized pigs, GH-secretagogue, L-
692,585, did not increase GH response which indicates pituitaiy is 
required for the normal GH secretagogue action. GH responses to L-
692,585 and ACTH were not different from GH response to PBS in 
h3T)ophysectomized pigs, but basal level of GH was persistant. GH may 
penetrate the blood barrier and contribute to the GH pool in systemic 
circulation because low levels of GH immunoreactivity persist in 
1 3 1  
hypophysectomized pigs. Local production of GH within the brain 
suggests that it has paracrine roles in modulating neural or 
neuroendocrine function. The GH secretagogue, L-692,585, releases GH 
from pituitary cell but whether a GH secretagogue such as L-692,585 
directly affects neural GH in vivo is questionable. 
There was a modest increase of ACTH in response to L-692,585 
and CRH in sham operated pigs, which was significantly higher than PBS 
treated group. Clinical importance of a modest increase of ACTH by GH 
secretagogue is unknown and seeing L-692,585 as a corticotropin 
secretagogue is still questionable. High ACTH levels after ACTH iv 
injection in HYPOX pig indicate validity of ACTH assay. The Cortisol level 
in HYPOX pigs by L-692,585 or CRH administration was in normal 
physiological range of Cortisol secretion and lower than in SOC pigs. 
ACTH administration in HYPOX pig caused a marked increased in 
Cortisol indicating validity of HYPOX surgery. Direct action by L-692,585 
to adrenal may not be existed, and L-692,585 has required of pituitary to 
induce GH release. The results indicate that the neither L-692,585 or 
CRH appear to have a direct effect on the adrenal gland to release 
Cortisol in HYPOX pigs. The results also suggest that the increase of 
ACTH by L-692,585 treatment in SOC pigs may involve CRH from brain 
origin. 
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An understanding of central nervous system mechanisms by which 
novel GH secretagogues such as L-692,585 stimulates GH secretion is of 
interest because of their biochemical simplicity, efficacy by oral 
administration, and potential application to affect growth in livestock 
species. 
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APPENDIX A. 
GLOSSARY OF TERMS 
PBS Phosphate Buffer Saline 
iv Intravenous 
icv Intracerebroventricular 
SOC Sham operated control 
HYPOX Hjrpophysectomized 
S.E. Standard Error 
GH Growth hormone (ng/ml) 
CRH Corticotropin releasing hormone (ng/ml) 
ACTH Adenocorticotropin (pg/ml) 
NPY Neuropeptide Y (ng/ml) 
SRIH Somatostatin (ng/ml) 
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APPENDIX B. 
TABULAR DATA OF INDIVIDUAL ANIMAL 
HORMONE RESPONSES 
Table A 1-2-1*. GH dose dependent response to L-692,585 administered icv at 3 ^ g/kg BW, 
ng/ml plasma 
Gilt Minutes 
No. -40 1 to
 
o
 
0 10 20 30 40 60 80 100 120 140 
Y0055 6.1 4.1 3.6 16.6 11.1 7.1 5.4 2.0 2.9 2.2 3.1 3.3 
Y0016 3.5 3.3 2.2 13.1 6.3 3.9 2.7 2.9 1.8 1.5 1.4 1.4 
Y0046 3.0 2.8 2.2 41.5 19.7 7.4 5.2 1.6 2.0 1.9 2.0 2.4 
mean 4.2 3.4 2.6 23.7 12.4 6.1 4.4 2.1 2.3 1.9 2.2 2.4 
S.E. 0.96 0.37 0.48 8.95 3.92 1.09 0.87 0.37 0.33 0.22 0.50 0.55 
* Chapter-figure-graph number 
Refer to Chapter 1, Figure 2, Page 33. 
Table A 1-2-2. GH dose dependent response to L-692,585 adnninistered icv at 10 Mg/kg BW, 
ng/ml plasma 
Gilt Minutes 
No. 
o
 t 1 to
 
o
 
0 10 20 30 40 60 80 100 120 140 
Y0055 2.8 2.1 3.0 43.3 4.5 11.4 0.9 3.5 1.6 2.4 1.7 2.0 
Y0016 1.9 2.3 1.8 15.2 24.4 5.1 3.3 2.0 1.9 1.6 1.6 1.8 
Y0046 2.7 2.3 2.7 47.8 8.5 12.2 7.7 3.3 2.8 2.2 1.8 2.2 
mean 2.4 2.2 2.5 35.4 12.5 9.5 4.0 2.9 2.1 2.1 1.7 2.0 
S.E. 0.30 0.05 0.35 10.21 6.09 2.24 1.98 0.46 0.35 0.24 0.07 0.12 
Refer to Chapter 1, Figure 2, Page 33. 
Table A 1-2-3. GH dose dependent response to L-692,585 administered icv at 30 Hg/kg BW, 
ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0055 2.6 2.1 2.7 33.0 8.5 9.5 6.1 3.2 1.2 1.9 2.1 1.9 
YOG 16 2.5 1.9 1.7 29.4 17.7 9.5 6.3 3.4 3.2 2.8 3.0 2.1 
Y0046 3.5 3.5 3.7 49.2 30.8 16.4 9.4 5.7 4.2 2.7 3.0 2.7 
Y0760 4.0 4.5 4.0 12.2 61.2 18.8 7.9 8.0 4.9 4.5 3.7 4.0 
Y0796 5.0 4.2 5.9 50.1 36.4 16.4 10.8 6.2 5.1 6.0 4.2 4.9 
Y0759 2.6 3.1 3.0 57.4 202.8 78.2 32.2 20.6 15.1 15.9 14.9 2.2 
Y0746 1.8 2.8 2.2 84.0 103.1 55.6 34.6 23.1 21.5 22.9 19.7 1.9 
Y0793 4.7 2.7 3.9 0.2 7.0 5.3 1.6 2.7 2.3 2.2 1.8 17.5 
Y0760 1.6 1.2 2.5 68.7 78.0 50.2 23.9 12.0 7.3 5.4 3.3 
Y0796 6.0 6.5 4.7 10.6 28.4 29.6 24.8 9.1 5.4 6.9 6.6 4.5 
Y0619 1.4 1.2 1.4 90.7 92.6 53.4 26.6 16.9 10.6 9.5 7.9 8.6 
Y0597 2.5 2.0 1.6 47.7 88.6 59.4 42.0 16.1 9.9 4.1 3.6 3.3 
Y0653 2.8 2.3 2.6 70.2 39.1 25.7 14.6 8.5 5.6 6.0 5.1 4.9 
Y0664 3.3 2.4 1.8 31.3 105.3 70.8 40.2 13.7 9.0 6.8 5.2 4.8 
Y0619 3.2 2.5 1.3 4.6 8.0 9.1 8.4 6.9 5.9 3.8 2.5 2.2 
Table A 1-2-3. GH dose dependent response to L-692,585 administered icv at 30 ng/kg BW, 
ng/ml plasma (continued) 
Gilt Minutes 
No. -40 1 to
 
o
 
0 10 20 30 40 60 80 100 120 140 
Y0597 2.2 1.7 2.2 12.8 22.7 17.5 13.4 8.4 2.5 2.6 2.5 2.8 
Y0796 9.2 10.4 8.0 150.1 92.2 35.7 19.5 9.8 9.3 6.6 7.4 6.4 
Y0759 7.3 6.1 6.5 156.3 100.0 38.0 27.0 13.9 9.4 8.8 8.0 4.7 
Y0746 2.5 2,8 3.3 3.1 3.4 4.3 5.3 5.1 8.5 4.2 4.3 3.3 
Y0760 4.8 7.7 2.6 84.3 40.7 28.7 14.8 7.2 5.3 3.6 2.8 2.2 
Y0796 4.8 6.6 5.3 3.3 69.2 62.0 44.6 18.6 4.9 8.7 7.4 5.5 
Y0759 1.8 3.1 3.4 6.5 19.8 27.7 27.0 11.5 5.9 5.4 4.5 4.2 
Y0619 2.0 1.9 4.0 4.1 4.8 3.9 6.7 10.3 8.1 9.6 9.1 
Y0653 1.6 1.2 1.3 8.9 10.5 6.8 4.2 3.0 2.3 1.6 1.3 1.3 
Y0664 1.3 1.3 1.3 22.8 23.0 13.0 8.0 4.5 3.0 1.3 1.5 1.2 
Y0619 1.2 5.1 7.2 60.3 35.2 25.6 16.0 10.2 7.3 6.6 6.4 3.8 
Y0597 5.4 5.2 4.7 18.1 18.7 11.1 5.9 2.9 1.8 2.1 2.6 2.4 
mean 3.4 3.6 3.4 42.3 49.5 30.0 18.7 10.0 6.9 6.0 5.4 4.3 
S.E. 0.38 0.44 0.37 8.28 8.82 4.55 2.74 1.21 0.87 0.89 0.79 0.63 
Refer to Chapter 1, Figure 2, Page 33. 
Table A 1-2-4. GH response to CRH administered icv at 150 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. 
o
 1 -20 0 10 20 30 40 60 80 100 120 140 
Y0016 2.2 2.0 2.2 2.2 4.2 4.5 3.8 3.2 3.3 3.2 3.6 2.4 
Y0016 5.3 2.9 2.9 2.7 2.4 2.3 2.7 2.9 2.6 3.7 5.6 4.3 
Y0046 3.9 2.8 3.5 3.3 3.2 3.3 2.6 5.0 4.4 5.0 7.0 6.0 
Y0046 4.9 3.6 4.2 3.9 4.0 3.1 2.4 2.1 2.5 2.9 3.0 4.2 
Y2903 0.7 1.2 1.3 1.2 3.8 0.3 0.8 0.7 0.8 0.7 1.1 1.6 
Y2874 0.8 0.7 0.4 1.5 3.6 2.0 0.8 0.6 1.0 0.9 0.3 0.6 
mean 3.0 2.2 2.4 2.4 3.5 2.6 2.2 2.4 2.4 2.7 3.4 3.2 
S.E. 0.82 0.45 0.58 0.42 0.28 0.58 0.48 0.68 0.57 0.68 1.04 0.82 
Refer to Chapter 1, Figure 2, Page 33. 
Table A 1-2-5. GH response to s^iline administered icv, ng/ml plasma 
Gilt Minntes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 3.3 2.8 3.5 4.6 3.6 3.2 3.6 3.2 3.5 2.4 2.8 2.7 
Y0760 1.7 2.3 1.9 2.1 1.9 3.1 4.6 3.0 1.5 2.1 2.2 2.4 
Y0796 5.1 4.1 4.3 3.3 2.8 3.4 2.7 4.0 2.1 4.0 4.5 5.5 
Y0796 2.7 4.0 0.7 3.1 1.8 3.3 3.6 4.7 3.4 5.3 4.9 3.2 
Y0725 2.8 3.4 2.6 2.7 2.5 3.6 3.9 4.3 4.9 2.7 2.7 
Y0725 4.1 4.7 3.8 2.1 2.7 2.1 1.1 2.4 2.5 3.0 3.4 2.3 
Y0759 4.2 2.8 4.7 2.4 2.2 2.3 1.7 1.7 2.3 1.6 2.1 2.9 
Y0759 1.8 2.8 2.2 2.2 2.7 2.0 0.6 3.1 3.5 4.8 3.2 2.0 
Y0746 3.2 3.0 2.9 6.2 6.8 6.4 6.0 4.9 3.1 3.8 3.5 2.5 
Y0746 5.9 2.9 3.9 2.2 3.2 3.0 2.7 2.7 3.8 5.1 2.8 3.3 
Table A 1-2-5, GH response to saline administered icv, ng/ml plasma (continued) 
Gilt Minutes 
No. -40 1 to
 
o
 
0 10 20 30 40 60 80 100 120 140 
Y0793 6.3 5,6 3.7 3.8 4.3 4.9 3.2 4.3 2.9 3.4 2.8 3.6 
Y0619 4.1 1.4 1.2 1.4 2.5 3.4 2.1 1.5 1.1 1.5 1.2 1.4 
Y0619 3.2 2.6 2.1 1.8 1.7 2.0 1.8 2.0 1.6 2.3 2.5 3.2 
Y0653 2.4 2.7 3.0 6.2 9.3 4.4 2.8 2.2 2.2 1.5 1.6 1.5 
Y0597 1.9 3.7 1.7 1.5 1.4 1.4 1.5 1.4 1.0 1.3 1.4 1.5 
Y0597 1.6 1.5 10.3 8.1 5.1 3.8 2.8 2.7 2.2 1.6 1.5 1.4 
Y0664 1.2 1.5 1.9 19.7 18.4 7.3 4.6 2.6 2.0 2.0 1,5 1.4 
Y0664 2.9 3.1 1.5 1.8 1.4 1.1 1.5 1.6 2.0 2.5 2.2 3.1 
Y0649 1.1 0.9 1.4 3.1 7.3 7.1 3.6 5.2 1.5 2.3 1.4 1.3 
mean 3.1 2.9 3.0 4.1 4.3 3.6 2.8 3.0 2.4 2.9 2.5 2.5 
S.E. 0.34 0.27 0.48 0.96 0.93 0.43 0.31 0.27 0.22 0.31 0.24 0.24 
Refer to Chapter I, Figure 2, Page 33. 
Table A 1-2-6. GH response to saline administered iv, ng/ml plasma* 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 2.1 2.3 2.1 2.3 2.7 2.9 2.3 3.9 3.7 6.2 3.5 4.3 
Y0760 2.4 2.9 9.7 2.9 1.2 2.2 3.5 3.8 4.3 5.2 1.2 1.8 
Y0796 3.7 2.9 2.3 2.0 2.6 2.8 3.7 3.5 3.7 4.7 5.7 4.1 
Y0796 8.8 10.9 5.7 6.0 5.9 7.1 4.3 3.5 4.8 6.3 5.2 1.9 
Y0725 2.2 1.9 2.9 3.1 4.3 4.3 2.8 2.5 1.2 2.1 2.0 1.7 
Y0759 2.3 1.7 1.9 3.6 3.5 2.5 3.0 2.8 2.6 2.6 2.8 2.8 
Y0759 2.1 3.0 2.2 3.1 2.3 2.5 2.7 2.2 2.4 6.0 6.1 6.4 
Y0746 5.5 4.7 6.0 9.2 5.6 3.8 2.9 2.5 2.9 2.5 2.4 1.7 
* Table A 1-2-5 and A 1-2-6 used together as a control in swithchback study. 
Table A 1-2-6. GH responses to saline administered iv, ng/ml plasma (continued)* 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
YOB 19 6.1 6.1 10.3 11.4 7.4 4.6 2.8 1.9 2.0 1.9 2.4 1.9 
Y0619 2.1 10.8 8.9 7.0 4.0 2.5 1.8 1.5 1.5 1.8 1.8 1.6 
Y0653 2.6 1.4 1.5 1.6 1.5 1.1 1.2 1.4 1.0 1.3 1.3 1.5 
Y0597 1.3 1.3 1.2 3.8 7.0 5.7 2.9 1.7 1.9 1.8 1.9 2.0 
Y0597 3.6 3.0 2.2 1.6 1.3 1.5 1.7 2.3 2.1 1.3 1.0 1.4 
Y0664 3.6 2.1 1.7 2.5 1.6 1.4 1.2 1.5 1.2 1.4 1.3 1.2 
Y0664 1.7 2.1 2.0 2.9 1.6 1.9 1.9 2.3 1.9 1.3 1.3 1.2 
Y0649 2.7 3.3 5.3 5.3 4.0 3.0 2.6 1.6 1.5 4.3 5.5 3.4 
mean 3.3 3.8 4.1 4.3 3.5 3.1 2.6 2.4 2.4 3.2 2.8 2.4 
S.E. 0.49 0.75 0.78 0.71 0.51 0.41 0.22 0.21 0.29 0.48 0.45 0.36 
* Table A 1-2-5 and A 1-2-6 used together as a control in swithchback study. 
Refer to Chapter 1, Figure 3-7 
Table A 1-3-1. Cortisol dose dependent response to L-692,585 administered icv 
at 3 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0055 20 20 4 29 21 8 11 7 9 3 4 11 
Y0016 48 42 30 97 58 79 57 48 34 94 53 44 
Y0046 18 14 11 29 18 13 15 3 3 10 9 23 
mean 28 25 15 52 32 33 27 20 16 35 22 26 
S.E. 9.7 8.5 7.7 22.7 12.9 22.8 14.8 14.4 9.5 29.1 15.4 9.8 
Refer to Chapter 1, Figure 3, Page 35. 
Table A 1-3-2. Cortisol dose dependent response to L-692,585 administered icv 
at 10 ^g/kg BW, ng/ml plasma 
Gilt Minutes 
No. 
o
 1 -20 0 10 20 30 40 60 80 100 120 140 
Y0055 10 16 4 46 56 48 41 24 7 34 32 33 
Y0016 12 32 27 80 42 18 18 30 19 48 24 14 
Y0046 13 8 7 29 17 12 11 26 42 24 37 9 
mean 12 18 13 52 38 26 24 27 22 35 31 19 
S.E. 0.9 7.0 7.1 14.8 11.3 11.2 9.2 1.7 10.2 7.2 3.8 7.2 
Refer to Chapter 1, Figure 3, Page 35. 
Table A 1-3-3. Cortisol dose dependent response to L-692,585 administered icv 
at 30 tig/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0055 32 39 20 51 48 34 27 16 28 48 28 35 
Y0016 33 15 10 99 65 19 34 11 27 23 14 43 
Y0046 16 15 15 39 52 17 11 6 5 10 8 13 
mean 27 23 15 63 55 23 24 11 20 27 17 30 
S.E. 5.5 8.0 2.9 18.4 5.3 5.5 6.9 3.1 7.7 11.0 6.0 8.9 
Refer to Chapter 1, Figure 3, Page 35. 
Table A 1-3-4. Cortisol response to CRH administered icv at 150 |ig/kg BW, 
ng/ml plasma 
Gilt Minutes 
No. 1 o
 
-20 0 10 20 30 40 60 80 100 120 140 
Y0016 71 60 68 8 69 107 127 143 158 162 88 31 
Y0016 67 151 64 101 106 90 61 53 49 79 84 97 
Y0046 124 141 95 54 50 52 61 112 50 55 26 30 
T0046 58 9 17 26 30 50 37 34 23 47 46 23 
Y2874 83 52 30 54 50 86 68 48 71 30 45 10 
Y2903 11 38 18 135 71 64 88 57 90 45 47 63 
mean 69 75 48 63 63 75 74 74 73 70 56 42 
S.E. 15.0 23.5 13.0 19.2 10.5 9.3 12.6 17.5 19.3 19.5 10.0 13.1 
Refer to Chapter 1, Figure 3, Page 35. 
Table A 1-3-5. Cortisol response to saline administered icv, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0055 19 15 22 79 31 22 19 53 34 36 11 8 
Y0016 16 21 20 10 17 9 9 13 16 17 12 16 
Y0016 42 8 14 15 7 17 59 25 26 12 4 23 
Y0046 5 6 25 30 35 62 94 121 83 56 32 54 
T0046 29 74 21 31 17 24 14 39 16 38 29 9 
Y2874 27 34 29 70 46 44 44 30 30 32 20 24 
Y2874 32 15 80 57 68 44 52 57 62 38 38 50 
Y2874 44 58 78 55 44 33 20 29 21 34 51 68 
Y2903 8 8 25 21 11 22 16 12 41 32 31 21 
mean 25 27 35 41 31 31 36 42 37 33 25 30 
S.E. 4.6 8.1 8.5 8.3 6.6 5.5 9.5 11.1 7.6 4.2 5.0 7.2 
Refer to Chapter 1, Figure 3, Page 35. 
Table A 1-4-1. GH cumulative responses to four iv injections of L-692,585 
at 30 MM/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0746 8.6 8.5 7.2 62.7 32.4 28.5 20.9 12.5 9.9 6.8 7.5 7.3 
Y0760 2.2 2.5 1.8 13.8 6.3 7.1 6.5 3.3 2.3 1.9 2.5 2.2 
Y0796 3.5 3.1 11.1 33.8 4.7 4.7 6.8 6.9 2.2 4.9 3.7 
Y0725 4.5 3.3 2.3 22.8 29.1 11.0 3.6 2.7 2.3 1.7 1.8 
Y0759 1.7 1.6 4.1 174.4 60.8 59.1 39.2 13.5 10.2 5.0 3.1 3.0 
Y0746 2.2 5.3 3.9 35.9 64.4 36.0 25.4 8.9 6.5 4.5 4.4 5.5 
Y0793 2.8 2.7 3.7 72.1 26.7 13.9 10.3 5.0 4.3 5.9 2.9 3.0 
Y0760 1.7 1.6 1.5 126.9 108.3 80.5 32.4 8.6 13.7 10.2 8.3 4.8 
Y0796 8.5 6.1 5.1 61.5 24.0 23.2 13.6 7.7 7.2 5.8 5.9 6.1 
Y0725 2.4 1.7 2.9 153.1 94.5 63.0 28.0 8.3 5.7 4.3 3.4 3.5 
Y0759 2.1 2.7 141.9 88.8 69,2 28.8 7.6 5.2 4.0 3.5 
Y0619 11.7 12.8 24.7 125.0 106.1 54.1 29.0 16.5 7.2 5.0 4.3 3.6 
Table A 1-4-1, GH cumulative responses to four iv injections of L-692,585 
at 30 Mfi/kg BW, nfi/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0597 1.6 1,7 4.4 69.6 129.4 33,8 17.6 7.2 3.1 2.3 1.9 1.8 
Y0653 1.9 2,0 2.1 28.9 11.3 7,3 4,9 2.9 2.8 1.3 1.4 1.4 
Y0664 2,4 3,8 6.6 139,5 60,0 34,6 23,7 13.0 10.0 5.0 4.5 4,3 
Y0649 1.9 2.1 1.5 41,4 19.9 10.8 5.5 2.1 2.4 2.0 2.1 2.5 
Y0619 1,5 1.9 2.7 54,3 30.8 20.4 15.5 8.0 3.6 2.6 2.2 2.0 
Y0597 1.9 3.0 3.4 46.1 29.8 15.5 11.0 6.1 3.5 2.4 2,0 1.8 
Y0664 1,4 2.4 3,2 110,1 46.5 19.9 14.2 7.3 4,2 2.6 2,1 1.8 
Y0760 4.5 4.6 5,8 48,8 11.7 4.3 2,8 2.1 1,4 2,4 2,5 1.9 
Y0796 3,6 3,3 4,8 147.3 89,5 50.6 24.0 8,1 4,0 1,1 3.7 3.8 
Y0725 0,5 1.8 2,1 26.3 37.8 15,0 7.4 3,6 2.9 2.4 3.5 3.2 
Y0759 1,9 2.3 3.1 71.1 106,4 56,7 27.2 9,7 6.0 3.9 3.9 3.5 
Y0746 2.5 2.2 2.0 47.0 25,3 14.0 10.2 3.7 3.2 5.0 5.7 6.4 
Table A 1-4-1. GH cumulative responses to four iv injections of L-692,585 
at 30 ng/kg BW, ng/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 1.9 2.6 2.4 139.0 87.1 47.2 26.2 10.9 6.2 4.0 4.3 8.0 
Y0796 1.5 0.8 2.8 16.6 23.9 15.1 9.6 4.3 2.9 3.0 2.6 3.2 
Y0725 1.5 2.6 3.1 96.0 13.9 7.6 4.9 3.8 4.1 4.1 4.7 3.1 
Y0759 3.6 3.3 3.9 274.1 118.2 49.5 26.8 11.1 7.0 6.4 5.1 5.3 
Y0619 2.3 1.7 55.9 39.1 21.4 13.9 5.6 3.5 2.5 1.9 1.9 
Y0597 1.9 1.1 2.5 58.7 43.4 23.6 16.7 6.9 3.7 2.5 1.9 1.8 
Y0653 1.5 1.9 2.2 52.2 21.8 7.6 4.2 2.4 2.2 1.4 1.8 1.6 
Y0664 1.5 1.8 2.4 149.7 60.5 26.0 16.5 6.4 3.2 2.1 1.8 1.7 
Y0649 1.1 1.9 124.9 40.2 17.0 10.1 4.3 3.4 1.0 1.3 1.4 2.9 
Y0619 3.7 2,5 2.9 90.4 35.7 22.0 10.9 6.9 4.2 2.6 2.4 2.2 
Y0597 2.9 2.1 2.2 25.8 20.8 9.1 5.0 3.7 2.2 2.1 1.9 1.8 
Y0664 2.1 1.5 1.7 48.7 24.3 16.3 8.5 5.5 4.3 2.6 2.2 2.0 
mean 2.8 3.0 7.1 80.0 50.0 28.0 15.6 6.9 4.8 3.5 3.3 3.3 
S.E. 0.38 0.41 3.43 9.56 5.98 3.41 1.63 0.59 0.47 0.32 0.28 0.29 
Refer to Chapter 1, Figure 4, Page 37. 
Table A 1-4-2. GH cumulative responses to four icv injections of L-692,585 
at 30 [ig/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 4.0 4.5 4.0 12.2 61,2 18,8 7.9 8.0 4.9 4,5 3.7 4,0 
Y0796 5.0 4.2 5.9 50.1 36,4 16,4 10.8 6.2 5.1 6,0 4.2 4,9 
Y0759 2.6 3.1 3.0 57.4 202,8 78,2 32.2 20.6 15.1 15,9 14,9 2,2 
Y0746 1.8 2.8 2.2 84.0 103,1 55,6 34.6 23.1 21.5 22.9 19,7 1,9 
Y0793 4.7 2.7 3.9 0.2 7.0 5.3 1.6 2.7 2.3 2,2 1,8 17,5 
Y0760 1.6 1.2 2.5 68.7 78.0 50,2 23.9 12.0 7,3 5,4 3,3 
Y0796 6,0 6.5 4.7 10.6 28.4 29.6 24,8 9.1 5.4 6,9 6,6 4,5 
Y0619 1.4 1.2 1.4 90.7 92,6 53.4 26.6 16.9 10.6 9,5 7,9 8,6 
Y0597 2.5 2.0 1.6 47.7 88,6 59,4 42.0 16.1 9.9 4,1 3,6 3,3 
Y0653 2.8 2.3 2.6 70,2 39.1 25,7 14.6 8,5 5,6 6,0 5,1 4,9 
Y0664 3.3 2.4 1.8 31.3 105,3 70.8 40.2 13.7 9,0 6.8 5.2 4.8 
Y0619 3.2 2.5 1.3 4,6 8.0 9.1 8.4 6.9 5,9 3,8 2.5 2.2 
Table A 1-4-2. GH cumulative responses to four icv injections of L-692,585 
at 30 ng/kg BW, ng/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0597 2.2 1.7 2.2 12.8 22.7 17.5 13.4 8.4 2.5 2.6 2.5 2.8 
Y0796 9.2 10.4 8.0 150.1 92.2 35.7 19.5 9.8 9.3 6.6 7.4 6.4 
Y0759 7.3 6.1 6.5 156.3 100.0 38.0 27.0 13.9 9.4 8.8 8.0 4.7 
Y0746 2.5 2.8 3.3 3.1 3.4 4.3 5.3 5.1 8.5 4.2 4.3 3.3 
Y0760 4.8 7.7 2.6 84.3 40.7 28.7 14.8 7.2 5.3 3.6 2.8 2.2 
Y0796 4.8 6.6 5.3 3.3 69.2 62.0 44.6 18.6 4.9 8.7 7.4 5.5 
Y0759 1.8 3.1 3.4 6.5 19.8 27.7 27.0 11.5 5.9 5.4 4.5 4.2 
Y0619 2.0 1.9 4.0 4.1 4.8 3.9 6.7 10.3 8.1 9.6 9.1 
Y0653 1.6 1.2 1.3 8.9 10.5 6.8 4.2 3.0 2.3 1.6 1.3 1.3 
Y0664 1.3 1.3 1.3 22.8 23.0 13.0 8.0 4.5 3.0 1.3 1.5 1.2 
Y0619 1.2 5.1 7.2 60.3 35.2 25.6 16.0 10.2 7.3 6.6 6.4 3.8 
Y0597 5.4 5.2 4.7 18.1 18.7 11.1 5.9 2.9 1.8 2.1 2.6 2.4 
mean 3.5 3,8 3.5 43.0 53.4 32.3 20.1 10.7 7.4 6.5 5.8 4.5 
S.E. 0.42 0.49 0.41 9.53 9.64 4.93 2.96 1.29 0.93 0.97 0.87 0.70 
Refer to Chapter 1, Figure 4, Page 37. 
Table A 1-5-1. GH ordinal response to first L-692,585 administered icv 
at 30 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. 1 O
 
lb
 
O
 
0 10 20 30 40 60 80 100 120 140 
Y0760 4.0 4.5 4.0 12.2 61.2 18.8 7.9 8.0 4.9 4.5 3.7 4.0 
Y0796 5.0 4.2 5.9 50.1 36.4 16.4 10.8 6.2 5.1 6.0 4.2 4.9 
Y0725 3.9 3.4 2.6 2.6 2.5 3.2 2.0 2.1 2.5 2.6 3.2 18.0 
Y0759 2.6 3.1 3.0 57.4 202.8 78.2 32.2 20.6 15.1 15.9 14,9 2.2 
Y0746 1.8 2.8 2.2 84.0 103.1 55.6 34.6 23.1 21.5 22.9 19.7 1.9 
Y0793 4.7 2.7 3.9 0.2 7.0 5.3 1.6 2.7 2.3 2.2 1.8 17.5 
Y0619 1.4 1.2 1.4 90.7 92.6 53.4 26.6 16.9 10.6 9.5 7.9 8.6 
Y0597 2.5 2.0 1.6 47.7 88.6 59.4 42.0 16.1 9.9 4.1 3.6 3.3 
Y0653 2.8 2.3 2.6 70.2 39.1 25.7 14.6 8.5 5.6 6.0 5.1 4.9 
Y0664 3.3 2.4 1.8 31.3 105.3 70.8 40.2 13.7 9.0 6.8 5.2 4.8 
Y0649 1.1 1.3 0.6 0.7 1.0 0.8 1.1 0.6 0.7 0.8 1.2 0.8 
mean 3.0 2.7 3,3 40.6 67.2 35.2 19.4 10.8 7.9 7.4 6.4 6.5 
S.E. 0.39 0.31 0.45 10.12 18.14 8.67 4.84 2.34 1.87 1.99 1.74 1.79 
Refer to Chapter 1, Figure 5, Page 39. 
Table A 1-5-2. GH ordinal response to second L-692,585 administered icv 
at 30 Mg/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 3.4 3.0 3.6 3.1 3.1 2.2 1.6 6.0 4.2 3.2 2.9 4.7 
Y0796 9.2 10.4 8.0 150.1 92.2 35.7 19.5 9.8 9.3 6.6 7.4 6.4 
Y0725 2.2 1.6 0.4 2.2 2.5 2.2 2.6 9.0 9.7 5.2 1.9 
Y0759 7.3 6.1 6.5 156.3 100.0 38.0 27.0 13.9 9.4 8.8 8.0 4.7 
Y0746 2.5 2.8 3.3 3.1 3.4 4.3 5.3 5.1 8.5 4.2 4.3 3.3 
Y0619 2.0 1.9 4.0 4.1 4.8 3.9 6.7 10.3 8.1 9.6 9.1 
Y0597 1.6 1.6 1.8 3.4 2.5 2.4 4.0 2.3 1.5 1.7 1.8 1.9 
Y0653 1.6 1.2 1.3 8.9 10.5 6.8 4.2 3.0 2.3 1.6 1.3 1.3 
Y0664 1.3 1.3 1.3 22.8 23.0 13.0 8.0 4.5 3.0 1.3 1.5 1.2 
Y0649 3.8 2.3 4.7 3.7 3.3 3.0 3.1 2.5 2.0 2.1 1.9 
mean 3.5 3.2 3.3 39.1 26.8 11.3 7.9 5.7 6.0 4.7 4.4 3.6 
S.E. 0.84 0.91 0.77 21.69 13.30 4.38 2.68 1.17 1.13 1.04 0.95 0.81 
Refer to Chapter 1, Figure 5, Page 39. 
Table A 1-5-3. GH ordinal response to third L-692,585 administered icv 
at 30 |ig/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 1.6 1.2 2.5 68.7 78.0 50.2 23.9 12.0 7.3 5.4 3.3 
Y0796 6.0 6.5 4.7 10.6 28.4 29.6 24.8 9.1 5.4 6.9 6.6 4.5 
Y0725 4.0 4.4 4.8 2.3 2.3 4.5 2.0 3.3 2.3 1.9 2.5 1.1 
Y0759 4.0 3.2 3.5 5.5 2.5 2.0 2.7 5.6 2.4 3.1 1.9 1.7 
Y0619 3.2 2.5 1.3 4.6 8.0 9.1 8.4 6.9 5.9 3.8 2.5 2.2 
Y0597 2.2 1.7 2.2 12.8 22.7 17.5 13.4 8.4 2.5 2.6 2.5 2.8 
Y0664 4.2 2.0 1.5 1.4 1.1 1.2 1.3 1.2 3.3 3.3 4.8 4.4 
mean 3.6 3.4 3.3 5.7 19.1 20.3 14.7 8.3 4.8 4.1 3.7 2.9 
S.E. 0.55 0.74 0.59 1.67 9.21 10.35 6.71 2.79 1.31 0.80 0.70 0.49 
Refer to Chapter 1, Figure 5, Page 39. 
Table A 1-5-4. GH ordinal response to fourth L-692,585 administered icv 
at 30 |ig/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 4.8 7.7 2.6 84.3 40.7 28.7 14.8 7.2 5.3 3.6 2.8 2.2 
Y0796 4.8 6.6 5.3 3.3 69.2 62.0 44.6 18.6 4.9 8.7 7.4 5.5 
Y0725 3.2 10.4 9.6 2.0 2.2 4.6 2.6 1.9 2.1 2.4 2.0 3.6 
Y0759 1.8 3.1 3.4 6.5 19.8 27.7 27.0 11.5 5.9 5.4 4.5 4.2 
Y0619 1.2 5.1 7.2 60.3 35.2 25.6 16.0 10.2 7.3 6.6 6.4 3.8 
Y0597 5.4 5.2 4.7 18.1 18.7 11.1 5.9 2.9 1.8 2.1 2.6 2.4 
Y0664 1.8 1.5 1.4 2.6 2.6 1.8 1.9 1.0 1.5 1.5 2.3 1.3 
mean 3.3 5.6 4.9 25.3 26.9 23.1 16.1 7.6 4.1 4.3 4.0 3.3 
S.E. 0.65 1.11 1.06 12.58 8.95 7.73 5.81 2.40 0.86 1.01 0.82 0.54 
Refer to Chapter 1, Figure 5, Page 39. 
Table A 1-6-1. GH iv response at 30 [ i g / k g  BW before L-692,585 administered icv, 
ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0746 8.6 8.5 7.2 62.7 32.4 28.5 20.9 12.5 9.9 6.8 7.5 7.3 
Y0760 1.7 1.6 1.5 126.9 108.3 80.5 32.4 8.6 13.7 10.2 8.3 4.8 
Y0796 8.5 6.1 5.1 61.5 24.0 23.2 13.6 7.7 7.2 5.8 5.9 6.1 
Y0725 2.4 1.7 2.9 153.1 94.5 63.0 28.0 8.3 5.7 4.3 3.4 3.5 
Y0759 2.1 2.7 141.9 88.8 69.2 28.8 7.6 5.2 4.0 3.5 
Y0760 1.9 2.6 2.4 139.0 87.1 47.2 26.2 10.9 6.2 4.0 4.3 8.0 
Y0796 1.5 0.8 2.8 16.6 23.9 15.1 9.6 4.3 2.9 3.0 2.6 3.2 
Y0725 1.5 2.6 3.1 96.0 13.9 7.6 4.9 3.8 4.1 4.1 4.7 3.1 
Y0759 3.6 3.3 3.9 274.1 118.2 49.5 26.8 11.1 7.0 6.4 5.1 5.3 
Y0619 11.7 12.8 24.7 125.0 106.1 54.1 29.0 16.5 7.2 5.0 4.3 3.6 
Table A 1-6-1. GH iv response at 30 |ig/kg BW before L-692,585 administered icv, 
ng/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0597 1.6 1.7 4.4 69.6 129.4 33.8 17.6 7.2 3.1 2.3 1.9 1.8 
Y0653 1.9 2.0 2.1 28.9 11.3 7.3 4.9 2.9 2.8 1.3 1.4 1.4 
Y0664 2.4 3.8 6.6 139.5 60.0 34.6 23.7 13.0 10.0 5.0 4.5 4.3 
Y0649 1.9 2.1 1.5 41.4 19.9 10.8 5.5 2.1 2.4 2.0 2.1 2.5 
Y0619 2.3 1.7 55.9 39.1 21.4 13.9 5.6 3.5 2.5 1.9 1.9 
Y0597 1.9 1.1 2.5 58.7 43.4 23.6 16.7 6.9 3.7 2.5 1.9 1.8 
Y0653 1.5 1.9 2.2 52.2 21.8 7.6 4.2 2.4 2.2 1.4 1.8 1.6 
Y0664 1.5 1.8 2.4 149.7 60.5 26.0 16.5 6.4 3.2 2.1 1.8 1.7 
Y0649 1.1 1.9 124.9 40.2 17.0 10,1 4.3 3.4 1.0 1.3 1.4 2.9 
mean 3.1 3.3 5.8 96.5 57.9 32.3 17.2 7.4 5.3 3.9 3.6 3.6 
S.E. 0.68 0.76 6.45 14.34 9.18 5.15 2.23 0.91 0.74 0.53 0.47 0.47 
Refer to Chapter 1, Figure 6, Page 41. 
Table A 1-6-2. GH iv response at 30 ^g/kg BW after L-692,585 administered icv, ng/ml plasma 
Gilt Minutes 
No. 
0
 1 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 2.2 2.5 1.8 13.8 6.3 7.1 6.5 3.3 2.3 1.9 2.5 2.2 
Y0796 3.5 3.1 11.1 33.8 4.7 4.7 6.8 6.9 2.2 4.9 3.7 
Y0725 4.5 3.3 2.3 22.8 29.1 11.0 3.6 2.7 2.3 1.7 1.8 
Y0759 1.7 1.6 4.1 174.4 60.8 59.1 39.2 13.5 10.2 5.0 3.1 3.0 
Y0746 2.2 5.3 3.9 35.9 64.4 36.0 25.4 8.9 6.5 4.5 4.4 5.5 
Y0793 2.8 2.7 3.7 72.1 26.7 13.9 10.3 5.0 4.3 5.9 2.9 3.0 
Y0760 4.5 4.6 5.8 48.8 11.7 4.3 2.8 2.1 1.4 2.4 2.5 1.9 
Y0796 3.6 3.3 4.8 147.3 89.5 50.6 24.0 8.1 4.0 1.1 3.7 3.8 
Y0725 0.5 1.8 2.1 26.3 37.8 15.0 7.4 3.6 2.9 2.4 3.5 3.2 
Table A 1-6-2. GH iv response at 30 ng/kg BW after L-692,585 administered icv, 
ng/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0759 1.9 2.3 3.1 71.1 106.4 56.7 27.2 9.7 6.0 3.9 3.9 3.5 
Y0746 2.5 2.2 2.0 47.0 25.3 14.0 10.2 3.7 3.2 5.0 5.7 6,4 
Y0619 1.5 1.9 2.7 54.3 30.8 20.4 15.5 8.0 3.6 2.6 2.2 2.0 
Y0597 1.9 3.0 3.4 46.1 29.8 15.5 11.0 6.1 3.5 2.4 2.0 1.8 
Y0664 1.4 2.4 3.2 110.1 46.5 19.9 14.2 7.3 4.2 2.6 2.1 1.8 
Y0619 3.7 2.5 2.9 90.4 35.7 22.0 10.9 6.9 4.2 2.6 2.4 2.2 
Y0597 2.9 2.1 2.2 25.8 20.8 9.1 5.0 3.7 2.2 2.1 1.9 1.8 
Y0664 2.1 1.5 1.7 48.7 24.3 16.3 8.5 5.5 4.3 2.6 2.2 2.0 
mean 2.5 2.7 5.8 61.5 40.7 23.1 13.8 6.2 4.2 3.0 3.0 2.9 
S.E. 0.27 0.26 0.27 11.15 6.81 4.24 2.36 0.71 0.52 0.32 0.28 0.33 
Refer to Chapter 1, Figure 6, Page 41. 
Table A 1-7-1. GH icv response at 30 ng/kg BW before L-692,585 administered iv, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 4.0 4.5 4.0 12.2 61.2 18.8 7.9 8.0 4.9 4.5 3.7 4.0 
Y0796 5.0 4.2 5.9 50.1 36.4 16.4 10.8 6.2 5.1 6.0 4.2 4.9 
Y0759 2,6 3.1 3.0 57.4 202.8 78.2 32.2 20.6 15.1 15.9 14.9 2.2 
Y0746 1.8 2.8 2.2 84.0 103.1 55.6 34.6 23.1 21.5 22.9 19.7 1.9 
Y0793 4.7 2.7 3.9 0.2 7.0 5.3 1.6 2.7 2.3 2.2 1.8 17.5 
Y0796 9.2 10.4 8.0 150.1 92.2 35.7 19.5 9.8 9.3 6.6 7.4 6.4 
Y0759 7.3 6.1 6.5 156.3 100.0 38.0 27.0 13.9 9.4 8.8 8.0 4.7 
Y0746 2.5 2.8 3.3 3.1 3.4 4.3 5.3 5.1 8.5 4.2 4.3 3.3 
Y0619 3.2 2.5 1.3 4.6 8.0 9.1 8.4 6.9 5.9 3.8 2.5 2.2 
Y0597 2.2 1.7 2.2 12.8 22.7 17.5 13.4 8.4 2.5 2.6 2.5 2.8 
Y0619 1.2 5.1 7.2 60.3 35.2 25.6 16.0 10.2 7.3 6.6 6.4 3.8 
Y0597 5.4 5.2 4.7 18.1 18.7 11.1 5.9 2.9 1.8 2.1 2.6 2.4 
mean 4.1 4.2 4.3 50.8 57.6 26.3 15.2 9.8 7.8 7.2 6.5 4.7 
S.E. 0.69 0.67 0.61 15.87 16.92 6.43 3.15 1.86 1.65 1.80 1.59 1.23 
Refer to Chapter 1, Figure 7, Page 43. 
Table A 1-7-2. GH icv response at 30 ng/kg BW after L-692,585 administered iv, ng/ml plasma 
Gilt Minutes 
No. 1 O
 
-20 0 10 20 30 40 60 80 100 120 140 
Y0760 1.6 1.2 2.5 68.7 78.0 50.2 23.9 12.0 7.3 5.4 3.3 
Y0796 6.0 6.5 4.7 10.6 28.4 29.6 24.8 9.1 5.4 6.9 6.6 4.5 
Y0760 4.8 7.7 2.6 84.3 40.7 28.7 14.8 7.2 5.3 3.6 2.8 2.2 
Y0796 4.8 6.6 5.3 3.3 69.2 62.0 44.6 18.6 4.9 8.7 7.4 5.5 
Y0759 1.8 3.1 3.4 6.5 19.8 27.7 27.0 11.5 5.9 5.4 4.5 4.2 
Y0619 1.4 1.2 1.4 90.7 92.6 53.4 26.6 16.9 10.6 9.5 7.9 8.6 
Y0597 2.5 2.0 1.6 47.7 88.6 59.4 42.0 16.1 9.9 4.1 3.6 3.3 
Y0653 2.8 2.3 2.6 70.2 39.1 25.7 14.6 8.5 5.6 6.0 5.1 4.9 
Y0664 3.3 2.4 1.8 31.3 105.3 70.8 40.2 13.7 9.0 6.8 5.2 4.8 
Y0619 2.0 1.9 4.0 4.1 4.8 3.9 6.7 10.3 8.1 9.6 9.1 
Y0653 1.6 1.2 1.3 8.9 10.5 6.8 4.2 3.0 2.3 1.6 1.3 1.3 
Y0664 1.3 1.3 1.3 22.8 23.0 13.0 8.0 4.5 3.0 1.3 1.5 1.2 
mean 2.8 3.3 2.6 34.4 49.2 38.3 25.1 11.6 7.0 5.8 5.1 4.4 
S.E. 0.45 0.73 0.41 10.11 9.94 7.32 4.71 1.82 0.92 0.77 0.73 0.72 
Refer to Chapter 1, Figure 7, Page 43. 
Table A 2-1-1. GH response to SRIF administered icv at 2 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. 
0
 1 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 6.2 6.6 7.3 5.6 3.1 2.1 2.7 2.7 2.7 2.2 1.4 1.5 
Y1488 3.2 2.1 1.6 1.7 1.6 2.6 1.8 1.7 2.3 2.4 2.0 1.6 
Y1495 1.9 2.0 1.8 1.5 2.7 3.4 3.2 1.6 1.6 1.6 1.5 1.1 
Y1477 6.0 5.3 7.6 4.4 4.1 3.3 3.0 1.4 1.6 1.7 1.4 2.0 
Y1476 1.3 3.0 2.3 1.5 1.4 0.8 1.8 1.7 1.9 2.0 1.4 1.2 
Y1476 3.3 3.3 3.0 2.5 2.3 2.3 2.8 1.9 2.3 3.4 1.6 1.5 
Y1450 2.2 2.7 2.3 1.1 2.1 1.9 1.9 1.4 1.6 2.2 1.4 0.5 
Y1450 2.1 2.4 2.6 4.1 2.5 2.4 2.7 2.0 2.5 3.6 3.4 3.7 
Y1365 1.4 2.0 1.9 1.9 2.0 1.7 2.1 1.5 1.8 5.1 3.9 3.8 
Y1365 1.7 1.5 1.7 1.5 1.1 1.1 1.1 1.3 2.1 4.6 5.8 4.5 
mean 2.9 3.1 3.2 2.6 2.3 2.2 2.3 1.7 2.0 2.9 2.4 2.1 
S.E. 0.57 0.51 0.72 0.55 0.35 0.33 0.26 0.15 0.13 0.48 0.57 0.45 
Refer to Chapter 2, Figure 1, Page 65. 
Table A 2-1-2. GH response to SRIF administered icv at 8 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 7.6 6.5 5.5 1.9 1.6 1.5 1.0 0.4 1.2 1.4 1.8 1.5 
Y1488 3,2 2.9 3.7 2.2 2.4 3.5 2.7 2.0 4.7 1.9 1.6 1.6 
Y1495 1.4 2.9 2.5 2.8 2.0 1.5 1.8 1.2 0.9 1.0 1.0 0.8 
Y1477 4.8 5.9 5.6 3.3 2.3 1.6 1.5 1.7 2.1 2.5 2.1 1.3 
Y1476 1.5 1.9 1.0 1.2 1.2 1.0 2.1 0.5 1.5 1.2 1.8 2.0 
Y1476 2.9 2.5 1.7 3.1 2.5 2.8 1.0 2.1 2.6 2.5 4.2 3.2 
Y1365 1.9 2.0 2.1 1.7 1.5 1.6 1.2 1.0 1.4 2.1 1.6 7.9 
Y1365 1.5 1.5 1.6 1.2 1.3 1.7 1.1 1.4 2.2 2.2 9.9 2.5 
mean 2.9 3.0 2.8 2.2 1.8 1.9 1.6 1.3 2.1 1.8 3.0 2.6 
S.E. 0.62 0.55 0.51 0.31 0.17 0.33 0.27 0.22 0.56 0.23 1.39 1.08 
Refer to Chapter 2, Figure 1, Page 65. 
Table A 2-1-3. GH response to SRIF administered icv at 2 |ig/kg BW + 
L-692,585 at 30 Mg/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 2.0 2.1 2.3 5.0 18.3 12.6 11.0 3.7 2.7 2.0 1.4 1.3 
Y1488 1.8 2.7 2.3 13.7 26.6 16.1 6.5 2.7 1.4 1.3 1.3 1.7 
Y1495 1.6 1.8 1.7 8.0 21.0 14.2 9.3 3.2 2.7 2.7 2.6 2.0 
Y1477 1.6 1.9 1.6 8.1 26.9 17.4 10.0 3.5 1.7 1.9 1.9 2.3 
Y1465 1.9 2.4 2.6 41.8 33.5 23.5 16.6 16.5 13.9 11.6 8.9 7.3 
Y1469 2.0 1.5 1.1 39.5 32.4 26.2 26.0 26.0 23.2 22.0 21.0 15.2 
Y1476 6.2 8.7 7.8 18.9 27.2 17.1 11.1 4.0 3.8 4.4 6.6 6.0 
Y1450 3.7 6.5 5.8 34.3 29.5 21.8 8.9 5.7 3.8 3.3 4.2 
Y1365 5.2 6.0 6.2 16.4 56.6 52.7 35.8 21.8 19.3 14.1 11.5 10.3 
mean 2.9 3.7 3.5 18.9 30.8 23.3 16.5 10.0 8.3 7.1 6.5 5.6 
S.E. 0.58 0.87 0.81 5.79 4.78 5.25 4.04 3.02 2.78 2.40 2.18 1.56 
Refer to Chapter 2,  Figure 1, Page 65. 
Table A 2-1-4. GH response to SRIF administered icv at 8 Mg/kg BW + 
L-692,585 at 30 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. 
o
 
1 
-20 0 10 20 30 40 60 80 100 120 140 
Y1487 1.4 1.9 1.6 12.4 17.7 13.0 6.7 2.0 1.9 1.1 1.5 1.9 
Y1488 1.4 1.9 1.5 23.4 21.7 15.2 6.3 2.1 2.0 2.1 1.5 1.7 
Y1495 1.4 1.3 1.4 15.8 14.6 9.8 5.4 2.4 1.9 2.0 2.1 1.5 
Y1477 2.1 2.3 2.1 18.0 27.0 13.8 6.6 2.1 2.2 1.9 1.8 1.5 
Y1465 5.5 5.0 4.9 20.9 40.4 41.3 22.0 15.3 17.9 17.9 21.9 19.4 
Y1469 6.6 10.2 8.4 40.5 61.9 26.5 13.9 6.8 7.6 25.4 10.7 10.8 
Y1476 6.2 4.7 4.9 16.6 11.1 6.6 5.3 4.2 6.2 6.0 4.0 3.0 
Y1450 4.4 4.9 4.3 22.0 13.0 24.3 26.4 22.7 16.9 14.4 
Y1365 5.2 6.0 6.2 16.4 56.6 52.7 35.8 21.8 19.3 14.1 11.5 10.3 
mean 3.8 4.2 3.9 20.5 31.4 22.4 12.8 9.0 9.5 10.3 8.0 7.1 
S.E. 0.73 0.94 0.81 3.08 6.87 5.85 3.88 3.02 3.10 3.25 2.54 2.25 
Refer to Chapter 2, Figure 1, Page 65. 
Table A 2-1-5. GH response to L-692,585 administered icv at 30 jig/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0055 2.6 2.1 2.7 33.0 8.5 9.5 6.1 3.2 1.2 1.9 2.1 1.9 
YOGI 6 2.5 1.9 1.7 29.4 17.7 9.5 6.3 3.4 3.2 2.8 3.0 2.1 
Y0046 3.5 3.5 3.7 49.2 30.8 16.4 9.4 5.7 4.2 2.7 3.0 2.7 
Y0760 4.0 4.5 4.0 12.2 61.2 18.8 7.9 8.0 4.9 4.5 3.7 4.0 
Y0796 5.0 4.2 5.9 50.1 36.4 16.4 10.8 6.2 5.1 6.0 4.2 4.9 
Y0759 2.6 3.1 3.0 57.4 202.8 78.2 32.2 20.6 15.1 15.9 14.9 2.2 
Y0746 1.8 2.8 2.2 84.0 103.1 55.6 34.6 23.1 21.5 22.9 19.7 1.9 
Y0793 4.7 2.7 3.9 0.2 7.0 5.3 1.6 2.7 2.3 2.2 1.8 17.5 
Y0760 1.6 1.2 2.5 68.7 78.0 50.2 23.9 12.0 7.3 5.4 3.3 
Y0796 6.0 6.5 4.7 10.6 28.4 29.6 24.8 9.1 5.4 6.9 6.6 4.5 
Y0619 1.4 1.2 1.4 90.7 92.6 53.4 26.6 16.9 10.6 9.5 7.9 8.6 
Y0597 2.5 2.0 1.6 47.7 88.6 59.4 42.0 16.1 . 9.9 4.1 3.6 3.3 
Y0653 2.8 2.3 2.6 70.2 39.1 25.7 14.6 8.5 5.6 6.0 5.1 4.9 
Y0664 3.3 2.4 1.8 31.3 105.3 70.8 40.2 13.7 9.0 6.8 5.2 4.8 
Y0619 3.2 2.5 1.3 4.6 8.0 9.1 8.4 6.9 5.9 3.8 2.5 2.2 
Table A 2-1-5. GH response to L-692,585 administered icv at 30 ng/kg BW, 
ng/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0597 2.2 1.7 2.2 12.8 22.7 17.5 13.4 8.4 2.5 2.6 2.5 2.8 
Y0796 9.2 10.4 8.0 150.1 92.2 35.7 19.5 9.8 9.3 6.6 7.4 6.4 
Y0759 7.3 6.1 6.5 156.3 100.0 38.0 27.0 13.9 9.4 8.8 8.0 4.7 
Y0746 2.5 2.8 3.3 3.1 3.4 4.3 5.3 5.1 8,5 4.2 4.3 3.3 
Y0760 4.8 7.7 2.6 84.3 40.7 28.7 14.8 7.2 5.3 3.6 2.8 2.2 
Y0796 4.8 6.6 5.3 3.3 69.2 62.0 44.6 18.6 4.9 8.7 7.4 5.5 
Y0759 1.8 3.1 3.4 6.5 19.8 27.7 27.0 11.5 5.9 5.4 4.5 4.2 
Y0619 2.0 1.9 4.0 4.1 4.8 3.9 6.7 10.3 8.1 9.6 9.1 
Y0653 1.6 1.2 1.3 8.9 10.5 6.8 4.2 3.0 2.3 1.6 1.3 1.3 
Y0664 1.3 1.3 1.3 22.8 23.0 13.0 8.0 4.5 3.0 1.3 1.5 1.2 
Y0619 1.2 5.1 7.2 60.3 35.2 25.6 16.0 10.2 7.3 6.6 6.4 3.8 
Y0597 5.4 5.2 4.7 18.1 18.7 11.1 5.9 2.9 1.8 2.1 2.6 2.4 
mean 3.4 3.6 3.4 42.3 49.5 30.0 18.7 10.0 6.9 6.0 5.4 4.3 
S.E. 0.38 0.44 0.37 8.28 8.82 4.55 2.74 1.21 0.87 0.89 0.79 0.63 
Refer to Chapter 2, Figure 1, Page 65. 
Table A 2-1-6. GH response to saline administered icv, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 3.3 2.8 3.5 4.6 3.6 3.2 3.6 3.2 3.5 2.4 2.8 2.7 
Y0760 1.7 2.3 1.9 2.1 1.9 3.1 4.6 3.0 1.5 2.1 2.2 2.4 
Y0796 5.1 4.1 4.3 3.3 2.8 3.4 2.7 4.0 2.1 4.0 4.5 5.5 
Y0796 2.7 4.0 0.7 3.1 1.8 3.3 3.6 4.7 3.4 5.3 4.9 3.2 
Y0725 2.8 3.4 2.6 2.7 2.5 3.6 3.9 4.3 4.9 2.7 2.7 
Y0725 4.1 4.7 3.8 2.1 2.7 2.1 1.1 2.4 2.5 3.0 3.4 2.3 
Y0759 4.2 2.8 4.7 2.4 2.2 2.3 1.7 1.7 2.3 1.6 2.1 2.9 
Y0759 1.8 2.8 2.2 2.2 2.7 2.0 0.6 3.1 3.5 4.8 3.2 2.0 
Y0746 3.2 3.0 2.9 6.2 6.8 6.4 6.0 4.9 3.1 3.8 3.5 2.5 
Y0746 5.9 2.9 3.9 2.2 3.2 3.0 2.7 2.7 3.8 5.1 2.8 3.3 
Table A 2-1-6. GH response to saline administered icv, ng/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0793 6.3 5.6 3.7 3.8 4.3 4.9 3.2 4.3 2.9 3.4 2.8 3.6 
Y0619 4.1 1.4 1.2 1.4 2.5 3.4 2.1 1.5 1.1 1.5 1.2 1.4 
Y0619 3.2 2.6 2.1 1.8 1.7 2.0 1.8 2.0 1.6 2.3 2.5 3.2 
Y0653 2.4 2.7 3.0 6.2 9.3 4.4 2.8 2.2 2.2 1.5 1.6 1.5 
Y0597 1.9 3.7 1.7 1.5 1.4 1.4 1.5 1.4 1.0 1.3 1.4 1.5 
Y0597 1.6 1.5 10.3 8.1 5.1 3.8 2.8 2.7 2.2 1.6 1.5 1.4 
Y0664 1.2 1.5 1.9 19.7 18.4 7.3 4.6 2.6 2.0 2.0 1.5 1.4 
Y0664 2.9 3.1 1.5 1.8 1.4 1.1 1.5 1.6 2.0 2.5 2.2 3.1 
Y0649 1.1 0.9 1.4 3.1 7.3 7.1 3.6 5.2 1.5 2.3 1.4 1.3 
mean 3.1 2.9 3.0 4.1 4.3 3.6 2.8 3.0 2.4 2.9 2.5 2.5 
S.E. 0.34 0.27 0.48 0.96 0.93 0.43 0.31 0.27 0.22 0.31 0.24 0.24 
Refer to Chapter 2, Figure 1, Page 65. 
Table A 2-2-1. GH response to NPY administered icv at 4 Mg/kg BW, ng/ml plasma 
Gilt Minutes 
No. 1 O
 
-20 0 10 20 30 40 60 80 100 120 140 
Y1487 1.3 2.4 2.0 1.4 1.5 1.0 1.5 1.6 2.6 3.3 3.3 3.4 
Y1488 1.4 2.4 1.6 1.0 1.6 2.4 1.6 0.6 1.7 1.7 1.9 1.2 
Y1495 2.1 1.7 1.3 1.8 2.1 2.9 1.9 0.7 3.6 3.0 3.1 4.0 
Y1477 2.6 2.6 2.1 1.7 1.8 2.3 1.8 1.9 2.5 3.2 3.1 2.5 
Y1465 1.7 2.4 2.1 1.8 2.0 1.5 2.2 5.3 1.9 2.8 2.2 2.8 
Y1469 1.5 1.1 1.6 4.3 4.5 4.4 8.1 5.0 4.7 3.7 3.4 2.4 
Y1476 2.2 2.8 2.5 1.4 3.2 1.9 9.3 2.4 3.2 2.4 3.6 3.5 
Y1450 5.4 9.2 10.4 12.1 11.4 8.6 7.1 11.0 2.6 8.3 2.0 1.6 
Y1365 3.6 2.7 2.9 1.6 1.3 1.6 1.4 2.6 1.9 1.4 2.3 2.4 
mean 2.4 3.0 2.9 3.0 3.3 3.0 3.9 3.4 2.7 3.3 2.7 2.6 
S.E. 0.45 0.79 0.95 1.52 1.38 0.97 1.09 1.09 0.32 0.67 0.22 0.30 
Refer to Chapter 2, Figures 2, Pages 67 & 69. 
Table A 2-2-2. GH response to NPY administered icv at 4 ng/kg BW + 
L-692,585 at 30 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 1.6 1.9 2.5 2.0 4.9 14.0 10.0 4.2 3.3 3.7 3.7 1.7 
Y1488 0.8 1.4 1.2 9.7 23.0 19.8 7.5 2.3 1.5 1.7 1.5 2.5 
Y1495 2.4 2.6 2.0 2.3 12.5 19.8 12.6 3.7 3.0 2.7 2.9 3.0 
Y1477 2.4 2.4 2.4 4.1 25.0 29.5 12.8 4.6 2.8 2.6 2.7 2.8 
Y1465 2.9 4.2 26.3 7.6 30.7 14.0 14.4 6.0 4.4 3.3 2.6 2.6 
Y1469 2.4 4.0 4.8 25.9 23.9 12.1 8.2 6.3 3.4 3.3 2.7 3.2 
Y1476 3.3 4.6 12.2 29.3 28.4 42.9 12.7 7.4 13.7 11.4 2.9 3.3 
Y1450 3.0 3.2 3.9 36.1 26.1 16.2 9.3 8.9 4.6 5.7 3.0 
Y1365 7.4 7.2 6.3 31.7 36.0 20.8 14.0 7.7 5.5 2.3 2.2 2.9 
mean 2.9 3.5 6.8 14.1 24.5 22.1 12.0 5.7 5.2 4.0 3.0 2.8 
S.E. 0.62 0.59 2.67 4.48 3.44 3.22 0.97 0.74 1.28 0.98 0.39 0.16 
Refer to Chapter 2, Figures 2, Pages 67 86 69. 
Table A 2-3-1. GH response to galanin administered icv at 4 Mg/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 6.2 4.3 3.9 2.2 2.4 1.9 2.0 1.6 2.6 2.5 1.8 1.3 
Y1488 1.6 2.5 2.3 4.5 5.4 4.8 3.6 1,3 1.0 0,9 0.8 0.7 
Y1495 5.3 6.0 5.9 11.0 15.8 13.3 8.8 1.8 1,8 1.7 1.6 1.6 
Y1477 1.8 2.2 2.7 2.2 2.5 2.0 2.5 1.9 2.1 1.7 1.5 1.9 
Y1465 5.2 5.7 6.2 14.5 10.4 7.7 9.0 4.3 3.7 3.6 4.0 6.2 
Y1469 6.6 5.3 4.6 1.6 10.4 9.0 8.5 3.7 3.3 3.3 12.1 7.1 
Y1476 5.8 4.9 5.4 1.7 9.6 11.3 8.5 6.3 2.9 2.6 9.6 5.5 
Y1450 4.4 8.4 4.4 16.2 19.6 15.2 6.2 4.5 3.1 2.4 11.4 10.1 
Y1365 4.4 3.7 3.9 15.9 19.3 16.3 6.5 4.7 2.2 1.8 4.1 10.2 
mean 4.6 4.8 4.4 7.7 10.6 9.1 6.2 3.3 2.5 2.3 5.2 5.0 
S.E. 0.60 0.63 0.45 2.76 2.63 2.17 1.09 0.59 0.28 0.29 1.52 1.25 
Refer to Chapter 2, Figures 3, Pages 71 8& 73. 
Table A 2-3-2. GH response to galanin administered icv at 4 ng/kg BW + 
L-692,585 at 30 Mg/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 3.0 2.9 2.5 31.6 29.8 23.9 9.3 3.3 3.0 3.4 2.4 2.6 
Y1488 1.6 1.8 1.6 41.6 23.3 5.2 4.5 3.3 3.6 2.9 2.0 
Y1495 2.4 3.5 2.9 28.6 43.9 21.8 15.2 5.7 4.1 3.7 2.5 2.3 
Y1477 3.2 2.2 2.0 47.7 22.9 7.2 3.4 4.2 4.0 2.6 2.3 
Y1465 7.0 9.0 9.1 39.0 36.5 21.9 19.3 8.9 4.5 7.2 3.6 6.0 
Y1469 6.7 7.5 9.3 39.2 38.5 27.3 20.1 10.2 4.9 6.3 5.7 5.1 
Y1476 4.1 3.6 5.8 55.2 40.1 28.2 19.1 11.6 4.4 4.5 3.8 4.3 
Y1450 7.4 15.6 8.1 36.8 21.8 13.6 13.0 14.9 3.7 3.1 3.4 3.6 
Y1365 7.8 3.3 4.2 60.4 37.5 24.1 15.3 7.6 3.9 3.4 3.4 3.1 
mean 4.8 5.5 5.1 41.5 35.5 23.0 13.7 7.8 4.0 4.3 3.4 3.5 
S.E. 0.80 1.51 1.04 4.48 2.79 1.82 1.83 1.32 0.20 0.47 0.33 0.46 
Refer to Chapter 2, Figures 3, Pages 71 & 73. 
Table A 3-1-1. GH dose dependent response to urocortin administered icv 
at 10 (ig/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 6.0 4.9 4.7 3.0 2.3 1.2 1.7 2.2 2.3 2.3 2.5 2.3 
Y1488 1.6 2.0 1.8 3.6 11.9 16.4 13.4 7.4 3.5 3.5 3.9 4.3 
Y1744 7.1 7.1 7.0 5.7 4.2 3.1 2.6 2.7 2.7 3.1 2.6 2.5 
Y1495 5.8 5.7 1.9 5.5 4.7 3.9 3.4 3.5 4.4 4.1 6.0 5.6 
Y1477 2.0 2.1 2.4 5.8 24.2 24.7 17.1 10.4 3.6 2.7 5.3 5.7 
mean 4.5 4.4 3.6 4.7 9.4 9.9 7.6 5.2 3.3 3.1 4.1 4.1 
S.E. 1.14 1.01 1.01 0.59 4.03 4.58 3.16 1.59 0.38 0.31 0.69 0.72 
Refer to Chapter 3, Figure 1, Page 83. 
Table A 3-1-2. GH dose dependent response to urocortin administered lev 
at 30 jig/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 2.2 3.8 1.5 2.6 9.7 17.9 11.1 5.2 3.7 3.6 2.3 2.6 
Y1488 4.8 6.1 6.8 7.0 7.6 6.7 4.6 3.0 3.4 2.3 1.8 1.2 
Y1744 2.4 3.2 1.7 1.6 2.1 2.6 5.1 4.9 6.2 4.1 3.3 2.9 
Y1495 1.5 1.8 1.1 1.6 2.1 3.4 4.6 4.7 5.9 4.4 2.5 2.6 
Y1477 1.3 1.2 1.0 7.2 8.7 7.0 4.3 5.1 3.9 4.5 3.4 2.5 
mean 2.4 3.2 2.4 4.0 6.0 7.5 5.9 4.6 4.6 3.8 2.6 2.3 
S.E. 0.62 0.86 1.11 1.29 1.65 2.73 1.30 0.40 0.60 0.40 0.30 0.30 
Refer to Chapter 3, Figure 1, Page 83. 
Table A 3-1-3. GH dose dependent response to urocortin administered icv 
at 100 ng/kg BW, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y1487 1.5 1.0 1.4 1.7 2.1 3.7 4.1 5.9 4.4 3.0 2.4 1.5 
Y1488 5.4 3.6 3.5 3.2 2.9 3.3 3.6 6.5 5.1 4.0 3.9 3.6 
Y1744 3.2 2.7 2.3 3.9 4.8 4.0 2.8 1.8 12.8 5.9 3.2 5.6 
Y1495 4.7 2.5 2.4 2.6 2.3 2.0 1.4 1.7 1.9 2.3 1.6 1.9 
Y1477 3.2 2.6 2.6 2.6 3.0 2.3 2.1 2.1 1.4 1.4 1.2 1.7 
mean 3.6 2.5 2.5 2.8 3.0 3.0 2.8 3.6 5.1 3.3 2.5 2.9 
S.E. 0.67 0.41 0.33 0.37 0.48 0.39 0.48 1.06 2.05 0.78 0.50 0.77 
Refer to Chapter 3, Figure 1, Page 83. 
Table A 3-1-4. GH response to saline administered icv, ng/ml plasma 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0760 3.33 2.80 3.52 4.58 3.56 3.17 3.64 3.21 3.49 2.36 2.81 2.69 
Y0760 1.72 2.32 1.87 2.14 1.92 3.08 4.59 3.00 1.53 2.11 2.20 2.37 
Y0796 5.08 4.08 4.28 3.28 2.83 3.42 2.72 3.95 2.14 4.04 4.53 5.50 
Y0796 2.66 4.00 0.68 3.06 1.84 3.33 3.59 4.66 3.37 5.30 4.92 3.15 
Y0725 2.84 3.37 2.62 2.74 2.52 3.57 3.85 4.33 4.91 2.66 2.65 
Y0725 4.12 4.66 3.82 2.12 2.74 2.08 1.10 2.35 2.45 2.96 3.41 2.34 
Y0759 4.15 2.81 4.70 2.40 2.21 2.33 1.68 1.66 2.31 1.62 2.11 2.88 
Y0759 1.81 2.76 2.17 2.17 2.65 2.03 0.60 3.08 3.47 4.75 3.23 1.98 
Y0746 3.24 3.01 2.89 6.15 6.78 6.36 5.98 4.91 3.11 3.81 3.49 2.53 
Y0746 5.85 2.92 3.92 2.20 3.22 3.04 2.66 2.73 3.84 5.06 2.84 3.26 
Table A 3-1-4. GH response to saline administered icv, ng/ml plasma (continued) 
Gilt Minutes 
No. -40 -20 0 10 20 30 40 60 80 100 120 140 
Y0793 6.3 5.6 3.7 3.8 4.3 4.9 3.2 4,3 2.9 3.4 2.8 3.6 
Y0619 4.1 1.4 1.2 1.4 2.5 3.4 2.1 1.5 1.1 1.5 1.2 1.4 
Y0619 3.2 2.6 2.1 1.8 1.7 2.0 1.8 2.0 1.6 2.3 2.5 3.2 
Y0653 2.4 2.7 3.0 6.2 9.3 4.4 2.8 2.2 2.2 1.5 1.6 1.5 
Y0597 1.9 3.7 1.7 1.5 1.4 1.4 1.5 1.4 1.0 1.3 1.4 1.5 
Y0597 1.6 1.5 10.3 8.1 5.1 3.8 2.8 2.7 2.2 1.6 1.5 1.4 
Y0664 1.2 1.5 1.9 19.7 18.4 7.3 4.6 2.6 2.0 2.0 1.5 1.4 
Y0664 2.9 3.1 1.5 1.8 1.4 1.1 1.5 1.6 2.0 2.5 2.2 3.1 
Y0649 1.1 0.9 1.4 3.1 7.3 7.1 3.6 5.2 1.5 2.3 1.4 1.3 
mean 3.1 2.9 3.0 4.1 4.3 3.6 2.8 3.0 2.4 2.9 2.5 2.5 
S.E. 0.34 0.27 0.48 0.96 0.93 0.43 0.31 0.27 0.22 0.31 0.24 0.24 
Refer to Chapter 3, Figure 1, Page 83. 
Table A 4-la-l. GH response to CRH administered iv at 150 Mg/kg BW in SOC pig, ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2451 3.5 3.0 3.4 3.6 2.1 1.3 1.5 1.4 1.8 1.8 1.7 1.9 2.0 2.6 2.5 
Y2718 3.1 3.3 2.4 2.9 2.8 2.4 1.9 2.2 2.7 4.2 2.0 2.9 3.2 4.1 3.8 
Y2656 4.4 3.7 4.8 6.3 4.4 4.1 3.6 2.9 3.7 5.0 5.6 3.5 2.8 4.5 1.5 
Y2714 4.7 4.2 5.8 4.6 2.5 2.1 1.9 2.5 3.0 2.4 3.1 2.4 3.1 2.0 3.0 
Y2451 4.6 2.1 1.8 2.2 1.8 1.8 1.9 2.5 0.8 1.4 2.0 1.4 1.4 1.1 1.3 
mean 4.1 3.2 3.6 3.9 2.7 2.3 2.2 2.3 2.4 3.0 2.9 2.4 2.5 2.9 2.4 
S.E. 0.32 0.35 0.74 0.72 0.45 0.47 0.37 0.25 0.49 0.70 0.72 0.37 0.34 0.64 0.47 
Refer to Chapter 4, Figure la, Page 104. 
Table A 4-la-2. GH response to L-692,585 administered iv at 10 ng/kg BW in SOC pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2451 4.6 4.2 4.2 88.8 38.9 16.8 9.8 19.0 14,1 7.4 5.3 2.7 2,8 3.1 2.8 
Y2718 2.0 2.3 1.7 71.1 42.6 19.5 13.1 10,3 7,7 6.5 6.1 3.8 5,8 5.8 1.5 
Y2656 6.7 6.7 4.7 68.6 61.7 25.3 11.6 9,3 6.6 4.5 4.8 2.3 2.8 3.2 3.9 
Y2703 1.0 2.0 1.5 78.2 40.3 23.8 12.9 8.1 5,5 4.1 4.2 3.3 4.0 3.5 2.4 
Y2714 7.0 5.3 2.4 61.5 26.1 15.2 9.5 5,6 3.4 2,5 4.4 1.2 1.4 3.4 4.9 
Y2451 1.9 2.4 2.5 14.0 3.7 2.5 1.8 1.9 1.8 
mean 3.9 3.8 2.8 73.7 41.9 20.1 11.8 10,4 7.5 5.0 4.8 2,6 3.1 3.5 2.9 
S.E. 1.06 0.78 0.54 4.63 5.72 1.95 0.76 2,27 1.80 0.88 0,34 0.37 0.65 0.52 0.52 
Refer to Chapter 4, Figure la, Page 104. 
Table A 4-la-3. GH response to L-692,585 administered iv at 100 Mg/kg BW in SOC pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2451 5.0 5.4 3.6 42.8 12.2 6.0 3.4 2.6 2.9 2.3 2.7 7.4 2.5 3.3 3.2 
Y2718 4.9 3.8 4.5 74.6 33.8 21.3 11.7 7.9 8.1 9.0 8.3 12.4 7.4 5.0 5.1 
Y2656 4.8 6.2 6.6 125.4 67.2 32.9 18.2 9.5 8.2 8.1 6.2 4.2 8.5 3.3 3.3 
Y2714 5.0 6.5 4.5 90.2 32.0 18.1 10.4 6.9 4.8 4.0 3.3 2.6 4.0 2.8 3.8 
Y2451 2.7 2.9 2.6 4.2 1.8 2.2 1.8 1.6 1.0 2.0 1,9 1.6 1.7 
mean 4.5 4.9 4.4 83.3 36.3 16.5 9.1 5.8 5.2 5.0 4.3 5.7 4.8 3.2 3.4 
S.E. 0.45 0.70 0.66 17.15 11.41 5.26 2.97 1.46 1.32 1.51 1.30 1.91 1.32 0.55 0.54 
Refer to Chapter 4, Figure la, Page 104. 
Table A 4-la-4. GH response to PBS administered iv in SOC pig, ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2656 7.5 5.1 5.2 3.5 4.2 3.9 2.8 6.7 4.6 3.8 3.7 3.3 2.5 4.3 5.3 
Y2714 5.4 7.1 5.6 4.5 4.3 4.5 3.4 4.6 4.1 2.7 3.2 3.2 2.5 4.5 3.2 
Y2703 4.1 3.3 2.8 1.7 1.7 1.3 1.7 2.4 2.3 3.2 4.1 5.0 5.0 3.2 3.3 
Y2451 3.0 1.8 1.2 1.2 1.4 1.5 1.2 15.5 26.4 2.9 2.2 3.2 2.3 3.2 1.4 
Y2718 4.7 4.7 4.9 3.8 3.8 3.9 4.7 2.8 2.9 4.2 5.2 5.1 5.2 3.1 7.2 
Y2451 1.7 1.3 1.5 1.6 1.5 1.7 2.1 1.9 1.8 1.7 1.7 1.8 2.0 
mean 4.4 3.9 3.5 2.7 2.8 2.8 2.6 6.4 8.1 3.1 3.4 3.6 3.2 3.4 3.7 
S.E. 0.81 0.88 0.80 0.57 0.58 0.59 0.53 2.39 4.59 0.34 0.51 0.52 0.61 0.39 0.89 
Refer to Chapter 4, Figure la. Page 104. 
Table A 4-lb-l. GH response to CRH administered iv at 150 |ig/kg BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2761 2.9 2.1 3.3 2.4 3.0 2.2 0.5 3.9 3.9 4.3 4.7 2.8 5.1 3.3 3.3 
Y2715 4.9 4.9 5.4 4.2 3.8 2.4 2.5 2.3 3.0 2.5 3.3 2.6 2.9 3.5 3.1 
Y2760 2.7 2.2 2.6 2.4 3.0 3.2 2.4 2.5 2.7 2.7 3.2 2.7 4.1 3.6 4.4 
Y2662 4.5 4.6 5.4 5.5 3.3 3.3 2.8 2.5 2.7 2.9 3.2 4.3 3.1 3.3 2.7 
Y2763 2.4 2.3 2.2 2.2 3.1 4.1 5.4 4.0 5.1 3.7 2.6 2.4 2.8 3.9 2.7 
Y2762 3.2 3.4 1.7 2.3 1.9 2.3 2.1 2.5 2.1 2.6 2.5 3.0 3.3 4.2 4.6 
Y0971 0.6 0.9 0.5 0.6 0.6 0.6 0.7 0.8 0.9 1.1 1.1 1.0 0.7 0.7 0.8 
Y1159 1.6 0.6 0.7 0.4 0.4 0.7 0.7 0.7 0.9 0.3 0.2 0.2 0.4 0.6 0,4 
Y0168 0.7 0.8 0.6 0.9 0.8 0.6 1.0 1.0 1.2 1.1 1.0 1.0 1.4 2.0 0.9 
Y1044 0.6 0.7 1.0 1.0 0.9 0.9 0.9 1.1 1.7 1.5 1.8 0.7 0.7 1.0 1.1 
Y1044 0.5 0.9 0.4 1.1 0.8 0.6 0.7 0.7 0.5 0.7 0.9 1.1 1.4 1.2 1.3 
Y0168 0.5 0.7 0.9 0.6 0.6 0.4 0.5 0.3 0.8 1.3 1.1 1.2 0.6 0.7 0.6 
mean 2.1 2.0 2.1 2.0 1.8 1.8 1.7 1.9 2.1 2.1 2.1 1.9 2.2 2.3 2.2 
S.E. 0.45 0.44 0.52 0.45 0.37 0.37 0.42 0.36 0.41 0.36 0.38 0.35 0.45 0.41 0.43 
Refer to Chapter 4, Figure lb, Page 106. 
Table A 4-lb-2, GH response to L-692,585 administered iv at 10 |ig/kg BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2692 2.2 2.3 3.1 2.5 3.5 1.9 1.2 1.5 1.7 1.5 2.0 1.8 1.3 1.9 
Y2760 2.4 2.6 1.6 1.9 3.1 1.9 1.8 1.6 2.1 2.2 2.5 3.1 4.0 3.8 1.3 
Y2662 5.3 5.6 3.1 3.3 2.7 2.5 3.1 2.6 3.8 3.7 2.9 3.0 3.3 2.7 4.0 
Y2762 2.7 4.3 4.1 4.3 5.1 3.1 2.3 1.9 2.4 1.9 
Y2761 4.8 6.1 5.7 4.1 3.5 2.9 2.6 3.4 3.7 3.1 3.4 3.6 3.5 1.5 3.6 
Y2715 6.0 4.9 4.8 4.8 4.6 5.9 4.0 3.8 4.6 0.8 3.5 3.7 3.4 4.5 5.2 
Y0971 0.1 0.7 0.9 0.9 0.5 0.7 0.7 1.3 1.1 1.2 1.5 1.6 1.8 0.8 0.8 
Y1159 0.6 0.5 0.5 0.5 0.4 0.5 0.5 1.0 1.5 1.4 0.5 0.7 1.0 0.7 0.2 
Y0168 1.1 1.0 0,8 1.0 0.8 0.9 0.9 0.9 1.6 1.7 1.9 0.8 0.7 1.1 0.8 
Y1044 1.7 0.9 1.0 0.9 0.9 0.9 0.8 1.2 1.4 0.5 1.1 1.0 1.1 0.9 1.1 
Y1044 0.9 0.8 0.8 0.7 0.6 0.6 0.9 0.7 0.8 0.9 1.2 1.2 1.5 0.9 0.8 
Y0168 0.9 0.7 0.5 0.5 0.6 0.8 0.7 1.1 1.0 1.3 0.6 0.6 0.6 0.4 0.6 
mean 2.4 2.4 2.3 2.1 1.9 2.0 1.6 1.7 2.4 1.8 1.9 1.9 2.0 1.8 1.8 
S.E. 0.57 0.65 0.54 0.46 0.47 0.49 0.35 0.32 0.44 0.29 0.29 0.36 0.35 0.38 0.50 
Refer to Chapter 4, Figure lb, Page 106. 
Table A 4-lb-3. GH response to L-692,585 administered iv at 100 Mg/^g BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2692 1.5 1.3 1.9 2.2 2.8 2.9 4.1 2.5 1.5 1.1 2.0 2.4 1.8 1.7 1.8 
Y2760 2.8 2.9 2.6 1.6 1.8 1.7 2.0 1.6 2.5 2.4 2.8 2.9 2.6 4.1 4.1 
Y2662 3.8 4.5 4.3 2.7 2.5 2.2 1.9 1.9 2.3 1.9 2.2 2.9 3.6 2.7 3.1 
Y2762 2.9 1.7 2.3 1.9 1.8 2.7 2.1 3.6 4.0 4.7 5.4 
Y2761 4.5 4.9 6.0 6.7 4.1 3.7 3.2 0.6 4.0 4.5 5.3 6.5 4.2 3.5 2.6 
Y2715 5.1 5.9 4.0 1.7 1.4 2.5 2.4 2.9 2.8 3.3 2.6 3.6 1.2 3.4 4.7 
Y0971 0.9 0.8 0.7 0.6 0.9 0.5 0.7 1.3 1.3 1.1 1.1 1.5 1.5 1.3 0.7 
Y1159 0.4 0.6 0.3 0.2 0.2 0.2 0.4 0.8 1.4 1.2 1.4 0.6 0.6 0.7 0.5 
Y0168 1.0 1.0 0.9 1.0 1.0 1.1 1.1 1.3 1.3 1.4 1.4 1.8 1.0 0.8 1.1 
Y1044 0.9 1.1 0.8 0.8 1.0 0.8 0.8 1.6 1.6 1.6 0,9 0.5 0.7 1.0 0.9 
Y1044 0.7 0.6 0.8 0.8 0.7 0.6 0.8 0.9 0.9 0.7 0.8 1.2 1.4 1.4 0.6 
Y0168 0.7 0.6 0.7 0.7 0.6 0.4 0.6 0.7 1.1 1.2 1.4 0.4 0.6 0.6 0.4 
mean 2.1 2.1 2.1 1.7 1.6 1.6 1.7 1.6 1.9 1.9 2.2 2.2 1.7 2.2 2.2 
S.E. 0.47 0.55 0.52 0.50 0.32 0.34 0.33 0.27 0.28 0.34 0.39 0.54 0.37 0.42 0.51 
Refer to Chapter 4, Figure lb, Page 106. 
Table A 4-lb-4. GH response to PBS administered iv in HYPOX pig, ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2692 2.9 3.1 3.2 3.0 3.2 2.0 1.6 2.3 2.0 1.7 1.7 2.2 1.9 1.9 2.0 
Y2760 1.7 1.8 2.4 2.0 1.8 1.8 2.3 2.2 2.4 2.8 3.3 3.7 4.4 2.7 2.1 
Y2662 4.4 2.8 2.8 2.5 2.6 2.8 2.7 2.3 2.6 2.2 2.2 3.4 3.3 3.5 4.1 
Y2685 2.1 1.0 1.2 1.5 1.0 0.9 1.1 1.4 1.7 1.7 1.5 2.3 2.7 3.1 3.5 
Y2660 2.0 2.5 2.0 1.9 1.5 1.9 2.4 2.0 1.9 3.7 1.4 1.1 1.2 1.4 2.9 
Y2763 3.1 3.8 3.7 4.2 3.7 2.6 0.8 1.9 1.7 2.7 2.0 2.7 1.9 2.4 2.8 
Y2762 2.8 2.9 2.1 2.2 1.4 2.6 2.0 2.4 2.1 2.7 2.3 2.8 3.2 3.4 3.2 
Y2761 5.7 6.2 3.8 4.8 2.8 2.6 2.7 3.4 3.1 3.7 3.2 2.9 3.6 3.4 5.6 
Y2715 4.1 3.6 3.2 2.7 2.4 2.5 2.2 1.2 2.6 2.7 3.1 2.8 4.1 4.8 8.3 
Table A 4-lb-4. GH responses to PBS administered iv in HYPOX pig, 
ng/ml plasma (continued) 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2715 4.2 4.2 5.2 5.3 3.1 3.2 1.6 2.5 2.6 2.6 2.3 2.6 2.5 3.5 3.9 
Y0971 1.3 1.1 1.1 0.9 0.3 0.8 0.7 1.2 1.3 1.4 1.6 0.8 0.9 1.4 0.9 
Y1159 0.4 0.7 0.6 0.1 0.6 0.7 0.5 0.2 0.1 0.3 0.5 0.6 0.7 1.2 1,2 
Y0168 1.1 1.0 0.8 0.8 1.0 0.7 1.0 1.0 1.2 1.0 1.0 1.4 1.9 1.6 1.9 
Y1044 0.7 0.8 0.6 1.1 0.5 1.0 0.8 0.9 0.9 0.9 0.8 1.1 1.1 1.4 1.6 
Y1044 0.8 0.9 0.9 0.8 0.7 0.6 0.7 1.1 0.2 0.3 1.1 0.6 0.9 0.9 0.6 
Y0168 0.7 0.9 1.0 0.8 1.0 0.9 0.8 0.5 1.0 1.1 1.0 0.7 1.2 1.3 1.6 
mean 2.4 2.3 2.2 2.2 1.7 1.7 1.5 1.7 1.7 2.0 1.8 2.0 2.2 2.4 2.9 
S.E. 0.39 0.40 0.35 0.38 0.27 0.23 0.20 0.22 0.21 0.27 0.25 0.29 0.33 0.31 0.52 
Refer to Chapter 4, Figure lb, Page 106. 
Table A 4-lc-l. GH response to ACTH administered iv at 150 Mg/kg BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 1.0 1.0 0.8 0.7 1.0 0.6 1.2 1.0 0,9 1.1 1.0 1.3 1,3 1,5 1.4 
Y1159 0,1 0.2 0.5 1.0 1.0 1.5 1.0 0,4 0,9 1.2 1.0 1.1 0,2 0,6 0.5 
Y0168 0,9 1.0 1.0 2.5 2.4 4.0 2.3 2,3 1.2 1.4 2.6 2.0 2,1 1,3 1.3 
Y1044 1.0 1.1 0.9 1.1 1.2 1.4 1.4 1,5 1,7 1.9 1.8 2.1 0.8 0,7 1.5 
Y1044 0.6 0.8 1.0 1.4 1.4 1.9 1.4 1,1 1.4 1.5 1.2 1.4 0,6 0,5 0.9 
Y0168 1.6 1.0 0.9 1,2 1.2 1.5 1.1 1,4 1.4 0.5 0.7 0.8 0,8 0,5 0.7 
mean 0.9 0.8 0.9 1,3 1.4 1,8 1.4 1.3 1.2 1.3 1.4 1.4 1,0 0,8 1.1 
S.E. 0.21 0.13 0.07 0.3 0.2 0.47 0.19 0.25 0.13 0.18 0.28 0.21 0.27 0.18 0.17 
Refer to Chapter 4, Figure Ic, Page 108. 
Table A 4-2a-l. ACTH response to CRH administered iv at 150 |ig/kg BW in SOC pig, 
pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2714 51 59 56 115 90 82 79 76 78 96 70 52 54 39 34 
Y2718 21 26 22 50 52 51 39 41 40 40 29 39 40 25 22 
mean 36 42 39 83 71 66 59 58 59 68 50 46 47 32 28 
S.E. 10.6 11.8 12.1 22.8 13.4 11.1 14.4 12.6 13.4 19.7 14.4 4.7 4.7 5.1 4.2 
Refer to Chapter 4, Figure 2a, Page 110. 
Table A 4-2a-2. ACTH response to L-692.585 administered iv at 10 |ig/kg BW in SOC pig, 
pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2714 27 30 33 93 48 36 32 29 28 33 27 29 33 27 30 
Y2718 22 17 13 149 72 43 31 30 24 33 31 24 21 40 20 
mean 24 24 23 121 60 40 32 29 26 33 29 26 27 33 25 
S.E. 1.9 4.6 6.8 19.8 8.7 2.4 0.4 0.3 1.2 0.1 1.5 1.7 4.4 4.7 3.5 
Table A 4-2a-3. ACTH response to L-692,585 administered iv at 100 ^ig/kg BW in SOC pig, 
pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2714 27 4 31 106 64 50 125 277 181 90 77 59 32 48 42 
Y2718 17 19 15 214 153 88 67 80 80 53 50 34 20 26 21 
mean 22 11 23 160 108 69 96 179 130 72 63 47 26 37 31 
S.E. 3.3 5.2 5.6 38.1 31.5 13.5 20.8 69.5 35.8 12.8 9.5 8.7 4.0 8.0 7.2 
Refer to Chapter 4, Figure 2a, Page 110. 
Table A 4-2a-4. ACTH response to PBS administered iv in SOC pig, pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y2714 23 25 25 25 24 28 30 23 25 24 27 33 23 29 27 
Y2718 20 20 15 13 19 33 161 51 80 57 35 25 21 42 29 
mean 22 23 20 19 21 31 96 37 53 41 31 29 22 35 28 
S.E. 0.9 1.9 3.5 4.2 1.9 1.9 46.5 10.2 19.5 11.5 3.0 3.1 0.8 4.7 0.7 
Refer to Chapter 4, Figure 2a, Page 110. 
Table A 4-2b-l. ACTH response to CRH administered iv at 150 mg/kg BW in HYPOX pig, 
pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 10 8 7 7 < 6.7 < 6.7 < 6.7 <6.7 < 6.7 < 6.7 < 6.7 < 6.7 7 
« 
7 
Y1159 7 7 7 11 7 11 7 8 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 
Y0168 67 47 44 42 56 45 64 54 51 38 
Y1044 7 7 8 7 < 6.7 < 6.7 < 6.7 <6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 
Y1044< 6.7 < 6.7 < 6.7 13 21 11 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 
Y0168 12 13 13 91 56 41 40 19 20 21 18 12 14 12 
Y2662 17 19 18 12 19 17 17 17 15 16 16 19 19 17 18 
Y2715 15 13 20 17 17 17 15 15 16 17 19 14 17 15 
Y2760 3 21 22 22 22 22 22 22 20 22 21 24 21 23 23 
Y2761 29 29 32 26 31 30 31 29 31 32 29 25 29 26 
Y2762 37 31 37 37 32 32 35 34 35 31 36 33 33 34 36 
mean 14 16 16 18 24 26 22 20 18 20 20 21 19 21 18 
S.E. 3.8 2.9 3.5 3.7 7.9 5.9 4.4 4.6 3.7 4.6 4.0 5.2 4.4 4.5 3.6 
Refer to Chapter 4, Figure 2b, Page 112. 
Table A 4-2b-2. ACTH response to L-692,585 administered iv at 10 mg/kg BW in HYPOX pig, 
pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 44 44 44 40 40 49 47 59 
Y1159 12 12 19 10 12 10 15 15 
Y0168 25 24 22 14 20 17 17 16 36 18 22 20 5 
Y1044< 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 7 7 
Y1044 57 34 56 40 25 24 26 8 7 9 
Y0168 18 26 21 47 43 26 38 31 22 17 11 13 14 
Y2662 20 22 22 19 19 20 15 18 3 17 22 21 19 16 21 
Y2715 19 15 17 21 18 18 22 21 18 19 23 22 19 19 26 
mean 21 21 22 18 23 28 23 27 24 20 20 19 12 12 15 
S.E. 4.5 4.6 4.3 4.8 5.6 6.8 5.2 6.9 6.8 3.3 2.7 2.6 2.6 2.5 3.7 
Refer to Chapter 4, Figure 2b, Page 112. 
Table A 4-2b-3. ACTH response to L-692,585 administered iv at 100 mg/kg BW in HYPOX pig, 
pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 35 38 42 47 55 65 50 46 
Y1159 9 17 13 14 11 21 15 15 
Y0168 24 18 36 19 16 33 24 36 14 18 37 66 18 14 
Y1044< 6.7 <6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 
Y1044 32 25 16 16 11 7 10 16 7 7 9 
Y0168 15 21 19 39 24 25 16 13 14 18 12 11 7 16 
Y2662 41 21 21 17 19 8 19 35 20 17 43 35 
Y2715 19 16 15 12 15 11 14 15 14 15 15 14 14 16 16 
Y2760 21 24 21 18 17 20 21 22 23 21 20 17 22 21 19 
mean 21 20 22 22 24 22 22 22 18 13 15 21 21 16 13 
S.E. 4.2 3.1 4.2 6.5 5.1 5.9 4.3 4.0 3.7 2.0 2.1 5.1 9.3 3.9 1.9 
Refer to Chapter 4, Figure 2b, Page 112. 
Table A 4-2b-4. ACTH response to PBS administered iv in HYPOX pig, pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 < 6.7 < 6.7 < 6.7 < 6.7 30 11 41 45 18 12 10 10 7 7 
Y1159 11 14 48 29 20 18 8 10 7 8 7 8 
Y0168 24 16 17 20 21 20 25 15 29 34 27 27 31 33 31 
Y1044< 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 
V 
o
 
>
 6.7 < 6.7 < 6.7 18 17 7 12 13 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 < 6.7 
Y0168 11 16 11 15 13 19 22 7 15 11 12 10 13 16 18 
Y2662 20 22 22 23 3 20 20 21 21 21 22 23 26 32 20 
Y2715 28 26 36 42 21 23 22 25 23 23 25 25 19 20 21 
Y2760 44 32 26 24 25 24 29 25 24 21 21 25 20 24 21 
Y2761 27 27 21 22 30 31 26 28 25 25 24 23 26 25 23 
Y2763 38 37 37 39 37 37 37 37 36 37 39 39 35 35 37 
mean 20 20 19 24 19 22 21 22 23 19 19 18 18 19 18 
S.E. 3.9 3.5 3.3 4.2 3.6 2.8 2.9 3.3 3.5 3.1 3.0 3.2 3.1 3.4 3.1 
Refer to Chapter 4, Figure 2b, Page 112. 
Table A 4-2c-l. ACTH response to ACTH administered iv at 150 mg/kg BW in HYPOX pig, 
pg/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 45 51 79 5750 5340 4227 3075 1697 1415 866 1146 441 331 722 613 
Y1159 10 9 19 2000 5534 5479 5343 3527 2690 3494 1921 1254 1446 701 370 
Y0168 13 16 13 2877 2302 2275 1738 1560 1309 1237 1188 1145 2188 286 332 
Y1044 < 6.7 < 6.7 < 6.7 3128 2852 1924 1208 786 56 13 42 40 36 96 
Y1044< 6.7 < 6.7 < 6.7 2111 1962 1998 2515 1223 1286 1181 1024 920 34 34 34 
Y0168 14 13 12 5827 2125 1826 1669 1862 839 369 306 350 35 15 15 
Y2761 26 26 28 1500 4284 1500 2782 2651 2263 2048 1303 1152 974 363 298 
Y2762 36 33 32 1973 2727 3294 1460 1761 1375 1046 1176 562 474 313 176 
Y2763 59 61 53 1500 1500 1500 1500 1500 1500 1260 1614 510 705 686 370 
mean 24 25 28 2963 3181 2669 2366 1841 1415 1438 1077 708 692 350 256 
S.E. 6.2 6.6 8.0 564.2 499.0 461.3 430.6 269.2 251.7 337.0 197.5 141.2 245.9 98.0 64.6 
Refer to Chapter 4, Figure 2c, Page 114. 
Table A 4-3b-l. Cortisol response to CRH administered iv at 150 ^g/kg BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 2 1 1 2 2 1 1 1 1 0 1 1 1 0 0 
Y1159 1 1 1 1 0 0 1 1 1 0 1 1 1 0 0 
YD 168 11 22 26 42 28 30 38 41 41 34 22 17 16 27 16 
Y1044 1 22 61 51 37 36 25 14 10 20 16 47 17 29 16 
Y1044 5 3 3 5 5 3 2 1 2 0 3 2 3 2 1 
Y0168 23 24 20 41 29 24 17 21 19 19 21 12 11 19 18 
mean 7 12 19 24 17 16 14 13 12 12 10 13 8 13 9 
S.E. 3.6 4.7 9.4 9.6 6.7 6.6 6.3 6.5 6.4 5.7 4.1 7.3 3.1 5.6 3.6 
Refer to Chapter 4, Figure 3b, Page 118. 
Table A 4-3b-2. Cortisol response to L-692,585 administered iv at 10 ng/kg BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 24 20 19 30 18 11 22 33 106 102 56 77 17 32 4 
Y1159 1 1 3 2 1 1 1 1 13 13 5 8 43 10 9 
Y0168 11 14 12 16 19 21 27 21 14 17 18 13 13 20 14 
Y1044 3 3 3 3 2 4 3 2 1 1 3 2 2 2 1 
Y1044 5 4 3 5 5 4 2 3 2 2 3 3 3 1 3 
Y0168 37 29 24 35 24 26 27 35 26 36 38 26 15 13 31 
mean 14 12 11 15 11 11 14 16 27 29 20 22 16 13 10 
S.E. 5.9 4.5 3.8 5.8 4.1 4.2 5.4 6.5 16.2 15.6 9.0 11.7 6.0 4.7 4.6 
Refer to Chapter 4, Figure 3b, Page 118. 
Table A 4-3b-3. Cortisol response to L-692,585 administered iv at 100 |4g/kg BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 23 21 19 25 26 21 32 34 112 51 101 56 79 6 70 
Y1159 4 1 4 1 1 1 1 1 11 7 11 4 12 45 8 
Y0168 11 10 10 15 14 9 9 11 14 9 9 10 13 10 8 
Y1044 2 2 2 3 3 2 4 2 3 2 3 2 3 3 1 
Y1044 6 4 3 3 2 2 2 3 2 3 4 2 3 2 4 
Y0168 43 33 30 28 12 19 16 11 15 10 10 12 27 16 17 
mean 15 12 11 13 10 9 10 10 26 14 23 14 23 14 18 
S.E. 6.3 5.2 4.5 4.9 4.0 3.6 4,8 5.1 17.3 7.5 15.6 8.5 11.8 6.6 10.5 
Refer to Chapter 4, Figure 3b, Page 118. 
Table A 4-3b-4. Cortisol response to PBS administered iv in HYPOX pig, ng/ml plasma 
Gilt Minutes 
No. 1 o
 
-15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 13 14 14 15 10 8 10 11 12 15 11 15 17 18 
Y1159 16 14 10 12 12 11 12 11 15 11 10 13 11 11 10 
Y0168 3 4 3 2 2 2 15 15 15 23 15 17 15 19 14 
Y1044 8 11 6 14 20 39 37 48 73 50 56 9 5 3 33 
Y1044 1 0 1 0 2 3 2 17 2 2 2 2 1 2 3 
Y0168 18 17 15 21 28 25 14 2 24 23 23 14 9 12 15 
mean 10 10 8 11 13 15 15 17 24 21 19 12 10 11 15 
S.E. 2.8 2.6 2.4 3.2 4.2 5.8 4.9 6.5 10.3 6.7 7.9 2.3 2.5 2.9 4.9 
Refer to Chapter 4, Figure 3b, Page 118. 
Table A 4-3c-l. Cortisol response to ACTH administered iv at 150 ng/kg BW in HYPOX pig, 
ng/ml plasma 
Gilt Minutes 
No. -30 -15 0 15 30 45 60 75 90 105 120 180 240 360 480 
Y0971 19 19 34 88 92 85 108 117 48 40 44 51 50 64 6 
Y1159 1 0 1 5 6 11 14 12 12 6 10 7 6 9 46 
Y0168 11 11 12 67 63 74 75 75 77 72 72 59 44 25 26 
Y1044 2 3 2 7 12 17 17 19 4 4 3 3 4 4 2 
Y1044 4 2 2 4 83 13 13 71 11 10 9 5 1 2 2 
Y0168 17 16 16 86 13 121 98 15 64 54 47 46 13 20 13 
mean 9 9 11 43 45 53 54 52 36 31 31 28 20 21 16 
S.E. 3.2 3.2 5.2 17.0 15.9 18.9 18.2 17.4 12.6 11.7 11.3 10.6 8.9 9.4 7.0 
Refer to Chapter 4, Figure 3c, Page 120. 
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